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Abstract
The ability to digest lactose depends on the expression and activity of intestinal
enzyme, lactase. In Finland, 17% of the population suffers from hypolactasia,
resulting in lactose maldigestion. Symptomatic lactose maldigestion is called lactose
intolerance. The aim of this study was to investigate factors which may either
improve or impair the digestibility of lactose and will thus affect the development of
maldigestion symptoms, and also the reliability of lactose intolerance diagnosis.
The possible regulatory role of gastric emptying in the digestibility of lactose was
studied in 18 maldigesters. In an oral lactose tolerance test, delaying gastric emptying
with propantheline improved tolerance to lactose by 26% (p=0.03), as measured by
the reduced area under the 12-h gastrointestinal symptoms score curve, compared to
the placebo. In a study with 9 lactose maldigesters, the temperature of the test
solution used in the test modified symptoms but had only minor effects on the other
maldigestion indicators. The effects of a cold test solution were more intense than
those of a hot one, and the former reduced flatulence (p=0.01) and abdominal
bloating (p=0.04) compared with the room temperature solution.
Inflammation markers were investigated in eight lactose maldigesters. In the urinary
excretion of prostacyclin metabolite (6-keto-prostaglandin F1α) a moderate increase of
about 30% (p=0.17), was seen following lactose intake. Ibuprofen, a nonselective
inhibitor of cyclo-oxygenases, tended to inhibit this increase (p= 0.02). In none of the
other indicators of inflammation used (e.g. nitric oxide production, blood leucocyte
count) were any differences observed compared with the controls.
In an experimental model, the effect of dietary lactose on the expression or activity of
lactase was tested for seven days with 8-week-old rats on a lactose-containing diet.
About 40% induction of lactase was noticed in the lactose-fed rats compared with the
controls (p=0.04), especially in the proximal and middle parts of the jejunum.
In the diagnosis of lactose intolerance, it was found that any one of the laboratory
variables used (breath hydrogen, blood glucose and urine galactose tests) was more
reliable than self-diagnosis. Only a third of the self-diagnosed subjects proved to be
real lactose maldigesters, and about the same proportion of the previously tested
subjects were, in reality, lactose digesters, indicating either a high incidence of
secondary hypolactasia or incorrect previous diagnoses.
It was thus shown that rather than being of inflammatory origin, lactose intolerance is
caused, at least partly, by motility disorders. This reduction of motility could be the
result of any factors, dietary or otherwise, which retard gastric emptying and/or
reduce intestinal motility. The continuous intake of lactose further improves
tolerance to lactose by increasing the expression and activity of the lactase, at least in
rats. Finally, we suggest that practical details, such as the temperature of the test
solutions, should be re-estimated in testing tolerance to lactose.
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1. Introduction
Lactose is a disaccharide consisting of glucose and galactose. It is found in milk and
other dairy products. The concentration of lactose in human milk is about 7%
whereas in cow’s milk it is about 5% (Palmiter 1969). The ability to digest lactose
depends on the presence of an enzyme (lactase) located in the small intestinal brush
border. The monosaccharides are then absorbed by active transport.
If the activity of lactase is low in the relation to the amount of lactose ingested, the
lactose cannot be hydrolysed to its components, resulting in maldigestion. This
situation is called hypolactasia (lactase nonpersistence, lactase restriction) and means
that there is low lactase activity in the jejunal mucosa. The term for the opposite of
hypolactasia is normolactasia (lactase persistence), and is applied to those with
moderate or high (‘normal’) lactase activity. Lactose maldigestion and lactose
malabsorption are terms to describe a poor lactose hydrolysing capacity. The term
lactose intolerance should only be used for a clinical entity, describing symptomatic
lactose maldigestion.
Reasons for lactose maldigestion can be classified as congenital lactase deficiency
(almost total lack of lactase, alactasia), hypolactasia (‘general’ lactose maldigestion)
and secondary hypolactasia (due to reversible injury in the gastrointestinal tract).
Lactase activity has a typical genetically-determined pattern during mammalian life.
This activity increases in late gestation and remains at a high level during early
childhood, whereafter it declines to the lower adult level (Sahi and Launiala 1978,
Flatz 1987). Hypolactasia may develop as a secondary condition in people already
suffering from other gastrointestinal diseases such as celiac disease or enteritis (see
Ushijima et al 1995, Gudmand-Høyer and Skovbjerg 1996).
The decline of lactase activity from the high infant level to the lower adult level is
the normal physiological pattern in about 75% of the world adult population, as
reviewed by Sahi (1994). The maintenance of high lactase levels occurs in only a few
populations, mainly in northern Europe. In Europe the incidence of hypolactasia
ranges from about 10% up to 70%. In Finland the incidence is less than 20% (see
Sahi 1994).
The inability to digest lactose will not always result in symptoms of intolerance
(abdominal pain, bloating, flatulence and diarrhoea) if lactose is consumed. The
terms lactose intolerance and lactose maldigestion are often used as if they were
11
synonymous, but they are not, in fact, the same. There are subjects who have a low
lactase hydrolysing capacity, i.e. they are hypolactasians but are still asymptomatic
after an oral dose of lactose (Rosado et al 1987, Scrimshaw and Murray 1988,
Carraccio et al 1998, Teuri et al 1999, Peuhkuri et al 2000b).
The most commonly used methods of diagnosing hypolactasia are the indirect
measurements of the breakdown products of lactose following an oral dose. Reduced
increase in blood glucose concentration, increase in exhaled breath hydrogen or
excreted urinary galactose all indicate hypolactasia (reviewed by Arola 1994).
The use of laboratory methods for diagnosing lactose intolerance (i.e. symptomatic
lactose maldigestion) is not sufficient. During a lactose tolerance test the
development of gastrointestinal symptoms must always be recorded side by side with
the laboratory results. Unhydrolysed lactose is transported to the colon and fermented
by colonic bacteria into short-chain fatty acids and gases (hydrogen, carbon dioxide,
and methane). The development of gastrointestinal symptoms depends on the
balance between the production and the removal of these fermentation products. If
the disposal capacity is exceeded, excessive rectal gas and/or abdominal distension
occur, as reviewed by Villako and Maaroos (1994). A hypolactasian subject who
suffers no gastrointestinal symptoms during the test is not lactose intolerant.
In the study of Teuri et al (1999) we showed the correlation between the blood
glucose concentration and gastrointestinal symptoms to be fair, between the
concentration of expired breath hydrogen and symptoms to be moderate, and
between the concentration of urinary galactose and symptoms to be good. In
practice, this means that if the blood glucose concentration alone is measured during
the tolerance test, as is the case in most Finnish health care centres (Peuhkuri et al
2000a), the number of incorrect diagnoses is likely to be significant.
In oral lactose tolerance tests the most widely used test dose in Finland is 50 g lactose
dissolved in 200 - 400 ml water (Peuhkuri et al 2000a). Newcomer et al (1978)
demonstrated that the majority of hypolactasian subjects develop gastrointestinal
symptoms following this dose. This equals the lactose found in a whole litre of milk,
and even normolactasians may suffer gastrointestinal symptoms after such a large
dose. The minimum dose of lactose needed to cause notable symptoms differs
between individuals. Most maldigesters are reportedly able to tolerate 12 g lactose if it
is consumed with a meal (Suarez et al 1995, Vesa et al 1996). However, there appear
to be no well-controlled trials in which a more natural dose of lactose (20-50 g) has
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been consumed in smaller doses divided between the meals, which is the usual
pattern of lactose intake.
The prevalence of lactose intolerance seems to be overestimated, and many people
who describe themselves as intolerant, whether tested by professionals in official
health care or not, are actually lactose digesters (Peuhkuri et al 2000b). Similar
results have been shown by other authors, too (Johnson et al 1993a, Suarez et al
1995, Saltzman et al 1999). Discussion of the principles for testing lactose tolerance
and possible affecting factors is very much needed.
Even though hypolactasia is fairly common in Finland, milk and other dairy
products are essential part of the Finnish food culture. This has inspired to several
series of studies on lactose intolerance, for example, of genetics (Sahi 1974a),
diagnostic methods (Arola 1988a) and gastrointestinal symptoms (Vesa 1997).
The aim of this study was to investigate factors which might possibly improve the
digestibility of lactose in the small intestine, thus affecting the development of
maldigestion symptoms, and also affecting the reliable diagnosis of lactose
intolerance.
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2. Review of literature
2.1. The lactase enzyme and its regulation
The brush border of the intestinal epithelium (microvilli) contains glycoproteins
which are responsible for the hydrolysis and absorption of dietary sugars. Lactose, the
disaccharide of milk, consists of galactose joined to glucose by β1,4-glycosidic linkage
(Figure 2.1). Before absorption this β1,4-glycosidic linkage must be hydrolysed by a
microvilli enzyme called lactase (lactase-phlorizin hydrolase [LPH]).
. 
LPH
Galactose Glucose
Galactose
Galactose
Glucose
Glucose
Figure 2.1. Lactose, which is made up of galactose and glucose molecules joined by
β1,4 -glycosidic linkage, is hydrolysed by lactase (LPH).
Lactase has two properties: lactase activity (β-galactosidase EC 3.2.1.23) and
glucosidase activity (EC 3.2.1.62). The lactase site splits lactose and cellobiose, and
some animal enzymes of this group also hydrolyse β-D-fucosides and β-D-glucosides.
The glucosidase activity hydrolyses phlorizin, glycosylceramides and other aryl- or
alkyl-β-glycosides, as reviewed by Keller et al (1993). However, lactose is the only
substrate of significant nutritional importance.
Despite these two activities, lactase is a single polypeptide. It is synthesized as a large
precursor of molecular weight, 205-245 kDa, and then processed to a mature enzyme
of varying molecular weight, from 120-130 kDa in the rat to 160 kDa in the human,
as shown in Figure 2.2 (Naim 1993). The variations in the molecular weights are
probably due to the different glycosylation patterns in the various species (Naim
1993). The primary structure of a lactase molecule consists of 1927 amino acids in
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humans, 1926 amino acids in the rabbit and 1928 amino acids in the rat (see Keller
et al 1993). Unlike sucrase-isomaltase, which is attached to the brush border
membrane from the N-terminal end of the protein chain, lactase is anchored by a
short hydrophobic C-terminal segment (see Keller et al 1993).
Pro-LPH
ER GOLGI BRUSH BORDER
Pro-LPH Pro-LPH Pro-LPH
LPH LPH
Human
Rat
ER GOLGI BRUSH BORDER
Pro-LPH Pro-LPH Pro-LPH
LPH (transient) + LPH LPH
Pro-LPH
LPH (transient)
Figure 2.2. Synthesis of lactase in humans and rats. In humans, the lactase precursor
(Pro-LPH) is synthetised and glycosylated in the endoplasmic reticulum (ER). In the
Golgi it is converted to a complex glycosylated molecule and is cleaved by trypsin-like
proteases (⇓). The final lactase (LPH) is transported to the brush border membrane.
Some Pro-LPH molecules may not be cleaved and are transported to the brush border
membrane and may be cleaved there by luminal proteases ( ). In the rat, Pro-LPH has
two potential cleavage sites and may be cleaved to transient or final LPH in the Golgi.
In the brush border membrane, uncleaved Pro-LPH and transient LPH are further
cleaved to LPH (Naim 1993).
Lactase exists only in mammals, but in other living organisms there are compounds
which are related to it. Lactase-related β-glycosidases and phospho-β-glucosidases
have been found even in eubacteria and fungi (see Keller et al 1993).
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2.1.1. Endogenous regulation
The relative activity of lactase is genetically determined and controlled by two alleles
at a single gene locus (Swallow and Harvey 1993). The lactase gene has been located
on chromosome 2q (Kruse et al 1988, Harvey et al 1993). In adults genetic
polymorphism determines a high or low messenger RNA (mRNA) expression and
activity (Harvey et al 1995). The mechanism for this polymorphism is not known but
it is presumed that sequence differences in the gene determine whether or not
lactose is down regulated (Wang et al 1998). Persistence of lactase (as measured by a
lactose tolerance test) is dominant to non-persistence (hypolactasia) (Sahi et al 1973,
Flatz 1987, Swallow and Harvey 1993). The activity in jejunal mucosa is less than 7
units/g protein in lactase nonpersistent subjects, and over 35 units/g protein in lactase
persistent subjects, as reviewed by Arola (1994). The level of lactase activity in the
heterozygotes is approximately half that of the persistent homozygotes (Swallow and
Harvey 1993) but sufficient in most cases to hydrolyse fully a 50 g lactose load in a
lactose tolerance test.
Most of the lactase activity in the rat develops late in gestation and stays at a high
level from just before birth till the time of weaning. After that, within a few weeks the
activity declines to the low levels of adulthood (Büller et al 1989). In the adult rat
lactase mRNA and protein are abundant only in the middle segment of the intestine
and are barely detectable in the duodenum and the ileum (Rings et al 1993). Studies
on rats have suggested that intestinal lactase activity further declines in old age (Lee
et al 1997).
The situation in humans is more complex. In the proximal small intestine of adults
with high lactase activity, lactase protein and activity are present in all villus
enterocytes. In hypolactasia lactase is patchily distributed on the villus enterocytes,
and even enterocytes in the very same villus differ from each other (Maiuri et al
1992, Rossi et al 1997).
The genetically programmed down-regulation of the lactase gene is detectable in
children from the second year of life (Wang et al 1998). In the Finnish population,
the usual age of the onset of the clinically significant decline of activity varies within
the 5-20-year range (Sahi et al 1972). Several factors have been implicated as the
cause of lactase decline at weaning or in human hypolactasia. The reduction of
(pre)pro-lactase synthesis has been associated with adult type hypolactasia (Witte et al
1990, Sterchi et al 1990, Lloyd et al 1990). A slow processing of the protein has also
been reported (Witte et al 1990, Sterchi et al 1990). The major control mechanism is
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now thought to be at the level of mRNA (Rossi et al 1997, Wang et al 1998), but the
heterogeneity of mRNA/activity ratio of lactase, even in a homogenous population,
probably indicates that other mechanisms, besides transcriptional regulation, may be
involved (Rossi et al 1997).
In lactase nonpersistence the activity of lactase in adults is about 5-10% of that found
in early childhood (see Büller and Grand 1990). A very rare condition is congenital
lactase deficiency (CLD) with an almost total lack of lactase (0-2% of activity of the
enzyme at birth) (Savilahti et al 1983). CLD is part of the so-called Finnish disease
heritage and the estimated incidence in the Finnish population is 1:60,000 births
(Savilahti et al 1983). The gene locus for congenital lactase deficiency is found to be
separate from but near to the lactase-phlorizin gene (Järvelä et al 1998).
2.1.2. Exogenous regulation
Milk and lactose
The role of milk, and lactose as a component of milk, in modifying the expression of
the lactase protein and its activity has been intensely studied during the past decades.
At weaning, when diet is changed from a milk-based to a mixed adult diet, the small
intestine undergoes functional maturation, as shown in many experimental studies
with rats. Lactase activity decreases and its longitudinal distribution is modified,
while the activity of other enzymes, such as sucrase-isomaltase (EC 3.2.1.10-48),
increases. Intestinal maturation in rats depends on an intrinsic ontogenic programme
(Duluc et al 1994) and on hormonal changes at weaning (Paul and Flatz 1983,
Freund et al 1991). Nutritional changes have been shown to accelerate or delay the
enzymatic decline and to modify the distribution of lactase mRNA in the small
intestine (Lebenthal et al 1973, Duluc et al 1992, Nsi-Emvo et al 1994).
Experimental studies of the role of milk and lactose can be divided into two groups
according to the age and the weaning stage of the animals. There have been
numerous experiments to prevent the physiological decline of lactase expression and
activity, by continued nursing, or by adding lactose to the diet immediately after
weaning (Table 2.1). The diet of control groups varies from conventional rat pellets
to a mixed diet with other di- or monosaccharides in the place of lactose. It is
impossible to compare the actual doses of lactose because of the inadequate
descriptions of the methods. The length of experimental periods varies from a few
extra days nursed to several months with added lactose in the diet. The conclusion,
however, is quite clear: dietary lactose, no matter what its source or the length of the
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test period, cannot prevent the physiological decline of lactase activity. In most of the
studies, however, the reduction in activity is smaller in the lactose treated groups
compared to the control groups on lactose-free diets.
Table 2.1. Effects of lactose or prolonged nursing on the expression and/or activity of
lactase in preweaned experimental animals.
Species,
age or weight
n Dose and source of
lactose
Length of
experiment
Lactase
A= activity,
E=expression
Reference
Rat, Sprague-
Dawley, male,
age ?
23 25% lactose / corn
starch in diet
6-11 wk A +25% Fischer 1957
Rat, Wistar,
30 - 60 d
Germ-free /
Conventional
44 Lactose, glucose or
maltose (70.5 g / 100 g
solids)
4-8 wk A +40%
compared
with glucose
after 30 d
Reddy et al 1968
Rat, Sprague-
Dawley,
40-50 g
16 5-60% lactose /
lactose- free
7 wk A + Cain et al 1969
Rat, Wistar,
4 wk
<100 10% lactose / lactose-
free
24 ,32 and
40 wk
A + Bolin et al 1971
Rat, albino,
2 wk
84 Lactose / glucose 8%
of total energy
2-16 wk A ± Sriratanaban et al
1971
Rat, age ? 40 Prolonged nursing /
conventional lactose-
free rat diet
2-4 wk A +120% Lebenthal et al 1973
Rat, Wistar,
1 d
40 30% lactose / glucose
+ galactose
2-11 wk A ± Leichter 1973
Rat, Sprague-
Dawley,
21 d
30 Powdered cow’s / rat’s
milk 20% of diet (w/w)
(1.6 - 2.5 g milk /day) /
no milk
0-10 wk A ± Becker et al 1974
Pig, Chester
White /
Hampshire,
5 mo
48 30% lactose (from
dried whey) / corn
starch in diet
3 wk A ± Ekström et al 1976
Rat, 0-27 d 8 Prolonged nursing 4 wk A & E +25% Sakuma et al 1996
Rat, Sprague-
Dawley, 0-27 d
<50 Prolonged nursing 4 wk A & E ± Motohashi et al
1997
+ = Increase ; ± = no change / effect
The number of experimental studies in which weaned adult animals were treated
with a lactose-containing diet is smaller than that of experiments with preweaned
animals (Table 2.2). The aim of these studies was to increase the low adult level of
lactase activity in order to regain the higher level of sucklings. The conclusion of
these studies was that dietary lactose can increase lactase activity to a level double the
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normal low adult level at the most, thus being about one fifth of the activity found in
suckling animals.
Table 2.2. Effects of dietary lactose on expression and/or activity of lactase in weaned
experimental animals.
Species, age
/weight
n Dose of lactose
(g / day)
Length of
experiment
Lactase activity Reference
Rat, Wistar,
female,
3 - 5 mo
34/
55
Lactose / glucose
30% of diet
2-31 wk + >50% in jejunum with
lactose and + 50% with
glucose
Bolin et al 1969
Monkey,
adult
7 Lactose 20% (dry
weight of diet)
7 wk + >30% in jejunum,
+ 70% in ileum
Wen et al 1973
Rat, 2 mo 33 Dose ?
goat’s milk
1-3 d + 100% in 24 h, no change
after 72 h
Added progesterone
injections increased activity
further
Goldstein et al
1974
Rat,
Sprague-
Dawley,
female, 2 mo
16 40% of energy as
lactose / sucrose
force fed
1 wk + 50% with lactose
compared with low-
carbohydrate diet
+100% with sucrose
compared with low-
carbohydrate, high-fat diet
Goda et al 1984
Mouse,
Swiss albino,
age ?,
32-33 g
48 Milk, fermented
milk or yoghurt
30% of diet (w/w)
0.5-2 wk + >25% in prox and >65%
in distal jejunum after 3 d
with fermented milk and
yoghurt
± with milk diet
Thoreux et al 1998
+ = Increase ; ± = no change / effect
In human studies there have been only a small number of subjects in whom lactase
activity was measured from small intestinal biopsies before and after the study period.
None of the studies showed any increase in lactase activity after a daily oral load of
lactose with increasing doses for ten days to 12 months (Cuatrecasas et al 1965,
Newcomer and McGill 1967, Kreusch et al 1969, Gilat et al 1972). The number of
subjects participating in these studies was three, two, 50 and ten respectively.
All these experimental (Tables 2.1 and 2.2) and human studies (Cuatrecasas et al
1965, Newcomer and McGill 1967, Kreusch et al 1969, Gilat et al 1972) to
investigate those factors affecting or controlling the physiological decrease in lactase
activity after childhood showed that dietary lactose did had minor effects. The same
conclusion was drawn from a different angle in a study in which suckling mice were
fed by transgenic α-lactalbumin-deficient females that produced lactose-free milk
(Jost et al 1998). The feeding pattern was thus physiological. In spite of the lactose-
free milk, the level of lactase activity and the longitudinal distribution of mRNA for
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lactase were unchanged compared to suckling animals nourished with normal
lactose-containing milk, indicating that the effect of dietary lactose is small. There
are no experiments to show how much lactase activity should increase in order to
significantly reduce gastrointestinal symptoms in lactose intolerant subjects.
Other dietary components
The possible effect of other dietary carbohydrates on lactase has mainly been studied
with rat models. A high carbohydrate diet for one week, with corn starch forming
70% of the total energy and with no added lactose, increased disaccharidase activity
(lactase, maltase and sucrase) in the rat jejunum (McCarthy et al 1980, Leichter et al
1984). Messenger RNA levels for lactase were elevated in rats fed a sucrose-enriched
diet (Goda and Takase 1994) within 12 h of a carbohydrate intake (Goda et al 1999).
This rapid accumulation of mRNA is thought to suggest that dietary sucrose
enhances the efficiency of the transcription of the lactase gene.
Oat saponins (a mixture of avenacosides A and B) in vitro inhibited lactase activity
(Önning and Asp 1995). This was not shown in in vivo studies in rats, probably due
to far lower concentrations of saponins in their diets (Önning and Asp 1995).
Saponins are thought to combine with the lactase enzyme and in this way to reduce
the activity. Concentrations of saponins found in oat products probably have no
effect on lactase activity in humans. Tannins have also been shown to reduce the
lactase activity in rats fed on a diet containing 4 g tannins /kg body weight (Thomsen
and Tasman-Jones 1982).
As shown by McCarthy et al (1980), a high fat diet is connected with low
disaccharidase activity. Recently it was demonstrated that the saturation of dietary fats
influences the activity of intestinal disaccharidases (Kaur et al 1996). Diets rich in
saturated fats (coconut oil) increased lactase activity in adult rats compared to the
control diet (commercial rat pellets). During a polyunsaturated fat diet (corn oil) or a
fish oil diet lactase was not induced compared with the control diet. In piglets
(Dudley et al 1994) the effect of the fat saturation level was the same as in rats.
Conflicting results of the effects of alcohol intake on lactase activity have been
reported. In an experimental study with adult rats after three months of ethanol
consumption (30% in drinking water [v/v]) lactase activity decreased (Rodriguez-
Castilla et al 1996). The same effect has been seen in previous in vivo (Baraona et al
1974) and in vitro models (Dinda et al 1979), and also in one human study with
alcoholic men (Perlow et al 1977). On the other hand, there are conflicting results in
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other experiments where no differences in lactase activity were found (Leichter 1987,
Rodriguez-Castilla et al 1996). In fact, low concentrations (1-3%) increased lactase
activity, at least in the epithelial cell line (Nano et al 1990).
Manipulating intestinal microflora by adding a probiotic (Probios®, Pioneer Hi-Bred
International Ltd, Johnston, Iowa, USA) to the diet of new-born piglets increased
lactase activity in the piglets at three weeks old, but in the post-weaning period the
differences in activity diminished and after about three months disappeared
altogether (Collington et al 1990). Oral treatment of adult volunteers with
lyophilized Saccharomyces boulardii for two weeks increased lactase activity, as
measured by intestinal biopsy, by almost 80% compared to the basal activity (Buts et
al 1986). The same effect was seen in adult rats on both viable and killed
Saccharomyces boulardii doses for five days (Buts et al 1986). No morphological
alteration of the intestinal mucosa was found either in humans or in rats. The
possible reason for this yeast-induced increase could be the stimulation of protein
synthesis at a translational level or the interference of proteolytic events of mature
lactase by yeast cells, as Buts et al (1986) concluded.
Reports from the field of dietary components that may modify lactase expression and
activity are fragmentary and unconsolidated. Only the surface of the subjects seems
to have been scratched. Dietary patterns are changing, and the actual role of such
factors as the whole diet or new dietary elements and functional foods on the capacity
of lactase to digest lactose has nor been examined. There is a definite need for further
investigation.
Stress factors
Lactose maldigestion may be caused by several diseases associated with injury in the
small intestinal epithelium, such as chronic inflammatory bowel disease and Crohn’s
disease; infectious gastroenteritis, whether of viral (rotavirus), parasitic (giardiasis) or
bacterial origin; and immunorelated injury such as sensitivity to gluten or
immunodeficiency syndrome (HIV), as reviewed recently by Ushijima et al (1995)
and Gudmand-Høyer and Skovbjerg (1996). A disease-induced decrease in lactase
activity is usually temporary and can occur at any age. This is called secondary
hypolactasia or secondary lactose maldigestion.
As seen above, lactase activity is depressed in celiac disease. The small intestinal
mucosa from patients with celiac disease in remission synthesizes brush border
membrane hydrolases like a normal (‘healthy’) mucosa. When challenged with
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gluten at a standard dose of 0.5 g/kg/day for one month, the tissue showed only slight
mucosal damage, but the biosynthesis of brush border membrane hydrolases was
reduced to the same level as in untreated celiac disease (see Lentze et al 1991). The
lactase enzyme is said to be one of the slowest enzymes to recover (see Lentze et al
1991).
Lactase activity in adult rats has been increased by starvation for 48 h (Freund et al
1989) and 72 h (Leichter et al 1987). However, in obese lactose persistent human
subjects, fasting resulted in the reduction of lactase activity (Knudsen et al 1968).
Feeding lactose or glucose after a two-week fast in a two-subject trial did not increase
lactase activity to the pre-fast level (Knudsen et al 1968). There seem, however, to be
no differences in lactase activity/g mucosal protein between genetically obese mice
(C57BL/6Jobob) and their lean controls, though there was difference in sucrase
activity (Flores et al 1990). Total lactase activity was greater in obese mice because of
their greater intestinal mass.
Drugs
The field of drug interactions on lactase expression and activity has scarely been
explored. Theoretically, any drug that impairs mucosal function or modifies its
structure may have an effect on lactase expression and/or activity.
It has been common knowledge since the late 50s that the broad spectrum antibiotics
such as neomycin, oral chlortetracycline and chloramphenicol reduce lactase activity
(Faloon et al 1958, Sharma and Majudmar 1970). In a more recent study a low dose
(i.p. 0.25 mg/g body weight) of actinomycin, which inhibits the transcription of
genes, slightly increased lactase activity, but a high dose (i.p. 1.5 mg/g body weight)
reduced this activity in hamsters in vitro (Andres et al 1985). A sucrose-induced
increase in lactase mRNA can be reversed by the injection of actinomycin D (50
µg/kg body weight) in rats (Goda et al 1999).
Derivates of 1-deoxynoijirimycin and acarbose, which are α-glucosidase inhibitors,
strongly inhibit sucrase activity without significantly affecting lactase (Lembcke et al
1985, Samulitis et al 1987). These types of α-glucosidase inhibitors have been
developed for the treatment of metabolic and gastrointestinal disorders such as
diabetes, obesity and the dumping syndrome (see Berger 1992).
In a series of short- and long-term experiments, Gill and co-authors showed the
inhibitory effect of two widely-used histamine H2-receptor antagonists, ranitidine (0.1
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- 1 mg/kg body weight) and cimetidine (0.003-2 mg/g body weight), on lactase
activity in mice in vivo and in vitro (Gill et al 1989, Gill et al 1990, Gill et al 1991).
They speculated that this adverse effect resulted from the chemical structure of these
drugs and their interaction with the lipids of cell membranes, but this needs to be
confirmed.
There are few studies of other drug-induced cases of the reduction or induction of
lactase. Colcicine, which was previously used to treat acute gout, administered orally
(50 µg/day) reversibly halved lactase activity in rats (Hudson and Smith 1986). In
organ culture, the glucocorticoid agent dexamethasone stimulated the production of
lactase in rats, but this effect was totally overturned by incubating the culture with
cycloheximide (0.5 g/ml), a protein synthesis inhibitor (Hudson and Smith 1986). In
hamsters, however, a dose of 1.5 mg/g body weight of cycloheximide produced no
change in enzymatic activity in vitro (Andres et al 1985). The immunosuppressive
agent cyclosporin A retarded normal maturation of the small intestine at the end of
weaning, thus retaining lactase activity longer and delaying the physiological increase
of sucrase and maltase activity in the rat (Cummins et al 1989).
As the studies referred to above show, further research is needed into drug-based
modifications of small intestine digestion and capacity to absorb nutrients. Drugs
affecting intestinal motility and thus the net absorption of lactose will be discussed
later.
2.2. Metabolism of lactose in the human body
In lactose-digesting subjects, after the β1,4-glycosidic linkage between glucose and
galactose has been hydrolysed by lactase, monosaccharides are actively transported
through the epithelial cell. Galactose is absorbed more efficiently than glucose.
Glucose enters the body glucose pool, but galactose is first metabolised to glucose,
mainly in the liver (Leloir 1951) (Figure 2.3). The regulating enzyme of this pathway
is UDP-galactose 4-epimerase. If galactose escapes hepatic metabolism, then it will
either be metabolised by the enterocytes or be excreted in the urine (Henderson et al
1982). Galactose concentrations in urine are about 10 times higher than those in
blood (Tengström 1968).
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Figure 2.3. Galactose metabolism to glucose.
In lactose-maldigesting subjects immediately following a lactose challenge, an
increased peristalsis was observed in jejunoscopy, at the same time as the mucosa
became hyperemic and edematous (Banai et al 1984). Increased quantities of
unhydrolysed lactose are present in the distal small intestine and the colon. The
result of this is a significant osmotic pressure. Water and electrolyte secretion into the
lumen increases. This osmotic flow will continue until equilibrium is reached
(Launiala 1968).
The human colon epithelial cells do not absorb lactose as such. The colonic flora in
each person is relatively stable but differs markedly between individuals (see Arola
and Tamm 1994). The factors affecting the composition and activities of the colonic
flora, and which could account for inter-individual variations, are largely unknown.
One preliminary study showed that high concentrations of Escherichia coli tended to
be associated with gas production in lactose maldigesters (Rautio et al 1999). Colonic
bacteria, some of which have β-galactosidase activity, will metabolise a proportion of
the lactose-producing short-chain fatty acids (SCFA) e.g. acetate, butyrate,
propionate. Some of these acids, especially butyric acid, are absorbed by the colonic
mucosa, to be used as substrate for the mucosa cells, but if the amount of SCFA
exceeds absorption capacity, the residue is excreted in the stools, which will become
acidic. The motor response of the colon to SCFA is complex. It seems that rather
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than inducing colonic transit time, at high concentrations SCFA may inhibit colonic
motility and thus participate in the adaptation of the colon to its contents (Cherbut et
al 1997).
The bacterial fermentation of lactose also produces gases such as carbon dioxide
(CO2), hydrogen (H2) and methane (CH4). There are also large inter-individual
variations in the activities of the flora that produces or consumes hydrogen. Excessive
gas production causes abdominal distension, pain, borborygmi and flatulence.
Excessive gas production and accumulation are strongly related to subjective
symptoms (Hermans et al 1997). In a study with lactose maldigesters, the subjective
symptoms did not correlate to the amount of malabsorbed lactose or to the volume or
the rate of gas accumulation per se, but rather to altered intestinal transit and
increased perception of luminal distension (Hammer et al 1996). These gases diffuse
into the portal circulation and their concentrations in exhaled air will increase and
can be used as an indicator of maldigested lactose.
The development of symptoms depends on the capacity of the colon to remove and
use lactose and its fermented intermediary metabolic products. If this capacity is
exceeded, gastrointestinal symptoms will develop. Women seem to be more liable
than men to produce symptoms from similar amounts of malabsorbed lactose
(Krause et al 1997).
The bacterial colonic adaptation of lactose maldigesters to a continued intake of milk
or lactose (Johnson et al 1993b, Hertzler and Savaiano 1996, Briet et al 1997) or of
totally unabsorbable carbohydrate lactulose (Flourie et al 1993, Florent et al 1985)
has been reported. This may be due to changed acidity in the colon caused by
unhydrolysed lactose. The metabolic production of gases is reduced with decreased
acidity (Perman et al 1981, Holtug et al 1992), suggesting more effective
fermentation. An increase in faecal β-galactosidase activity has also been found after
continuous ingestion of lactose (Hertzler and Savaiano 1996). Rather than metabolic
adaptation, Briet et al (1997) suggested that improved tolerance was just a placebo
effect, because clinical improvement was also observed in the control group, which
received sucrose.
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2.3. Motility and lactose-induced gastrointestinal symptoms
2.3.1. Neural and hormonal control of gastrointestinal motility
The purpose of mixing and propulsive movements in the gastrointestinal system is to
increase the contact of the luminal contents with the mucosal surface and to move
the chyme along the tract. These movements are a result of the contraction and
relaxation of the smooth muscle cells, which are arranged along the gastrointestinal
tract longitudinally, obliquely (as in the stomach) and circularly (see Moffet et al
1993) (Figure 2.4).
PARASYMPATHETIC
PREGANGLIONIC
NERVE FIBRE
MYENTERIC
PLEXUS
SUBMUCOSAL
PLEXUS
Effector: 
longitudinal muscle
Effector:
circular
muscle
Effector:
gland
Mucosa
Submucosa
Extrinsic input
Hormonal
extrinsic
control
Figure 2.4. Enteric nervous system based on Moffet et al (1993). Even though the
myenteric plexus primarily controls muscle contraction and the submucosal plexus
controls secretion, they are extensively interconnected.
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The main categories of movement are peristaltis and segmentation (see Moffet et al
1993). Peristaltis is composed of waves of contraction and relaxation of the
longitudinal and circular muscle layers, resulting in the movement of chyme along
the length of the tract. It is strongest in the swallowing pattern of the oesophagus,
moderately strong in the stomach, and relatively weak in the intestine. Segmentation
is the contraction activity of the circular muscle layer in order to mix the intestinal
contents. The relationship and connection between propulsive and mixing
movements is still under investigation (see e.g. Stevens et al 1999, Wood 1999).
Gastrointestinal motility is regulated by myogenic, neural and hormonal factors. In a
fasting state the migrating myoelectric complex (MMC) passes along the intestine
with the intense rhythmic contractions of the circular muscle (Szurszewski 1969, see
Kunze and Furness 1999). It is followed by periods of less intense activity and rest.
MMC clears the stomach and the small intestine of food remnants, intestinal
secretions and other contents. It has been called the ‘intestinal housekeeper’
(Vantrappen et al 1977). The fasting motility pattern is interrupted by food and
changed to continuous, irregular contractility.
The interdigestive MMC activity and the fed state activity are generated by the
enteric nervous system and modified by extrinsic nerves. The enteric nervous system
consists mainly of two plexuses (see Kunze and Furness 1999) (Figure 2.4). The
myenteric plexus (Auerbach’s) is located between the longitudinal and circular
muscle layers, and the submucosal plexus (Meissner’s) is in the submucosa. The
enteric nervous system covers the whole gastrointestinal tract from the oesophagus to
the anus. The myenteric plexus mainly controls gastrointestinal movements, and the
submucosal plexus is responsible for gastrointestinal secretion and local blood flow.
Even though the enteric nervous systems is an independent controller of the
gastrointestinal system, the stimulus from parasympathetic and sympathetic systems
can further activate or inhibit gastrointestinal functions. In addition, there are some
reflexes from the gut that transmit signals for long distances in the gastrointestinal
tract, such as gastrocolic reflex and enterogastric reflex (see Moffet et al 1993).
Understanding of different neurotransmitters released by the nerve endings is
increasing (see Kunze and Furness 1999, Lindberg 1999). In addition to the classical
neurotransmitters acetylcholine and noradrenaline a number of other transmitters
are also known. In many studies to investigate possible regulators of MMC, such as
insulin, opioids, calcitonin, motilin, and nitric oxide, some of these factors have been
shown to act via the enteric nervous system and others via neural connections from
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the brain (see McConalogue and Furness 1994, Lindberg 1999). Nitric oxide may
act as a messenger directly on the smooth muscle cells in regulating fasting intestinal
motor activity (Russo et al 1999).
The motility effects of gastrointestinal hormones are minor to their secretory effects
(Moffet et al 1993). Cholecystokinin is one with at least a moderate motility effect. It
is secreted by the mucosa of the duodenum and the jejunum in response to dietary
fats, fatty acids and monoglycerides. It releases bile into the small intestine by
increasing the contractility of the gall bladder. It also moderately inhibits stomach
motility and thus slows the emptying of the stomach, as does the gastric inhibitory
peptide. Secretin is another gastrointestinal hormone with some slight effect on
motility. It has mild inhibitory influences on most of the gastrointestinal tract
motility. Motilin is released when the pH of the duodenal chyme is over 4.5. It
facilitates digestion by increasing the strength of gastric contractions and the tone of
the pyloric sphincter.
Visceral hypersensitivity
Visceral hypersensitivity has been recognized as being responsible for both motor
alterations and abdominal pain in the pathophysiology of functional digestive
disorders, particularly in the IBS (see Mayer and Raybould 1990, Mayer and Gebhart
1994, Bueno et al 1997).  The role of afferent nerve pathways from the gut to the
central nervous system have been emphasized, and it seems that in some IBS patients
the pain threshold or response may be altered, and normally non-painful distension is
sensed as being painful.
There are only a few studies on the sensitivity to pain of lactose intolerants.
Whitehead et al (1990) compared tolerance to stepwise distension of a balloon in the
rectosigmoid and to holding one hand in icy water, in irritable bowel patients, lactose
maldigesters and asymptomatic controls.  The lactose maldigesters had the lowest
tolerance to icy water and the second lowest tolerance to balloon distension. On the
other hand, in a recent study with previously carefully tested lactose maldigesters, an
increased tolerance to ischemic pain was noticed compared to the asymptomatic
healthy controls (Ylitapio 1997). In a questionnaire study these lactose maldigesters
reported more frequent stomach pains than the controls, and the pain was more
disturbing than to the controls. According to these studies it is possible that at least
the lactose maldigesters possess reduced tolerance to visceral pain (visceral
hypersensitivity), even though reports on tolerance to experimental pain produced by
balloon distension or ice cold water have been conflicting.
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2.3.2. Exogenous factors modifying intestinal motility and the digestion of
lactose
Dietary components and nutrient content of the diet
Gastric emptying. The inhibition of gastric peristaltis, and thus the slowing of gastric
emptying, by chemical or mechanical stimulation of the mucosa of the duodenum is
called enterogastric inhibitory reflex. As there are receptors in the stomach and the
duodenum which respond to volume, to osmotic pressure, to acids, fats, fatty acids
and amino acids, and which thus control gastric emptying (see Cooke 1975,
Malagelada 1990) many dietary manipulations have been carried out. By increasing
viscosity or osmolality, and by increasing the energy, fat or carbohydrate content of
test meals, gastric emptying has been delayed (Holt et al 1979, Foster et al 1980,
Shafer et al 1985, Sandhu et al 1987, Vist and Maughan 1995).
It has been suggested that by delaying gastric emptying and thus increasing substrate
mucosal contact time, the amount of undigested lactose can be reduced. This was
investigated in studies where lactose was ingested in the form of milk with varying
energy and fat contents (Welsh and Hall 1977, Dehkordi et al 1995, Vesa et al 1997a,
Vesa et al 1997b), or as yoghurt (Marteau et al 1990, Arrigoni et al 1994, Mahe et al
1994), or with added ingredients such as chocolate (Welsh and Hall 1977, Dehkordi
et al 1995), lactic acid bacteria (Dehkordi et al 1995), starch (Vesa et al 1997a), and
fibre (Nguyen et al 1982), or as a part of a test meal (Solomons et al 1985, Martini
and Savaiano 1988). All these factors are known to modify gastric emptying and thus
the conclusion that lactose digestion is improved by retarding gastric emptying is
justified. However, the relationship between pure lactose and gastric emptying,
without the possible interference of the contents of milk or other dietary
components, osmolality, viscosity or the consistence of diet has not been well
documented.
The recent study of Barnet et al (1999), which is published only as an abstract,
showed that previous exposure to lactose affected gastric emptying. The investigators
speculate that this supports the inhibitory role of the intracolonic fermentation of
lactose in the control of gastric emptying, which may explain frequent upper
gastrointestinal symptoms in lactase nonpersistence.
Intestinal motility. Many factors that are known to delay gastric emptying also reduce
intestinal motility and transit time. In many studies it is actually hard to distinguish
the dietary effect on gastric emptying and on intestinal motility.
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There are many studies investigating the role of dietary components in the
interdigestive (postabsorptive) MMC. Food interrupts it and changes the motility
pattern to a postprandial state. Even intravenously, certain nutrients, at least amino
acids (Gielkens et al 1999), may modulate the interdigestive cycle of MMC. In one
experimental study, the postprandial disruption of the MMC depended much more
on the physiochemical composition of the diet than on its volume or energy content
(De Wever et al 1978). In an other study, however, the caloric value of a meal
regulated the duration of the fed state activity in the human small intestine without a
‘physiological ceiling’ of calories, at least for the normal caloric range per meal (220 -
1100 kcal) (Schönfeld et al 1997).
Of the dietary components, lipids are shown to have a stronger inhibitory effect on
MMC than glucose, peptides or a mixed meal, when perfused with duodenal canula
(Schang et al 1978) or eaten by conscious dogs (De Wever et al 1978, Eeckhout et al
1984). The infusions of nutrients (Schmid and Ehrlein 1993) or ethanol (Charles
and Phillips 1995) in the proximal jejunum of dogs showed the same kind of change
in the motility pattern as infusions in the upper parts of the intestine.
Coffee is said not to promote intestinal motility, as reviewed by Boekema et al (1999).
Even if caffeine perfusion studies resulted in a net jejunal and ileal fluid secretion,
no effect on small bowel transit time could be observed (Wald et al 1976).
Nevertheless, Aranda-Michel and Giannella (1999) advise anyone suffering from
diarrhoea to avoid caffeine-containing products because caffeine increases cyclic
AMP levels and thus promotes the secretion of fluid, and may worsen the diarrhoea.
In the late postprandial state, the lower small intestine also regulates the proximal
gastrointestinal motor function. In humans, intra-ileal perfusions with carbohydrates
(Layer et al 1990, Gröger et al 1991, Layer et al 1993) or fats (Layer et al 1990, Layer
et al 1993), simulating the late postprandial state, induce changes in the motility
pattern of the intestine from the fed state to the interdigestive state, by activating
MMC. These results are interesting because some of the carbohydrates, such as
lactose, may be malabsorbed and thus reach the lower parts of the intestine under
normal physiological conditions. However, in an experimental study with dogs,
carbohydrate infusion of starch and glucose in a ratio of 3:1 in the proximal colon did
not affect intestinal motility (Tohno et al 1995).
A very interesting study would be the intra-ileal perfusion of lactose and the
subsequent measurement of its possible action on gastric emptying and upper
gastrointestinal motility. In the study of Barnet et al (1999) this model is partly tested,
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but without the measurements of intestinal motility. There may also be a connection,
other than the osmotic diffusion of water, between undigested lactose in the contents
of the proximal intestine and the motility of upper parts of the intestine.
The consistency of the diet affects not only gastric emptying but also intestinal
motility. In healthy humans the liquid part of a test meal (polyethylene glycol PEG
4000) appeared in ileal aspirates 1-2 h postprandially and always earlier than the solid
part of the test meal (beans) (Kerlin and Phillips 1983). Ileal flow was shown to
increase postprandially and to remain at a high level for at least 3 h.
In conclusion, dietary contents modify gastric emptying and alter intestinal motility
on the whole length of the small intestine. The role of dietary delay on gastric
emptying and lactose digestion has  been well demonstrated. The effect of lactose on
MMC and thus on intestinal motility has not been studied.
Intestinal inflammation
In many intestinal inflammatory diseases in which symptoms resemble those found
in lactose intolerance, the endogenous synthesis of prostaglandins increases (see
Hawkey and Rampton 1985, Rask-Madsen 1986). Prostaglandins are synthesised via
the cyclo-oxygenase pathway (constitutive COX-1 and inducible COX-2) from
arachidonic acid. They stimulate the contraction of the gastrointestinal smooth
muscle and provoke many inflammatory responses such as vasodilation, vascular
permeability and hyperalgesia (see Ooms and Degryse 1986, Rask-Madsen 1986,
O’Loughlin et al 1991, Barrett and Bigby 1995).
If lactose-induced gastrointestinal symptoms are, at least partly, caused by local
intestinal inflammation, the possible increase in the endogenous synthesis of
prostaglandins after an oral load of lactose should be prevented by the inhibitors of
prostaglandin synthesis and thus should reduce gastrointestinal symptoms. This has
been investigated in only a few studies, with conflicting results. Premedication with
900 mg acetylsalicylic acid did not reduce lactose-induced symptoms in 12 lactose
maldigesters (Flatz and Lie 1982). In previous studies, however, the inhibition of
prostaglandin synthesis by acetylsalicylic acid (900 mg), indomethacin (25 mg), or
ibuprofen (400 mg) reduced symptoms caused by incompatible food in three out of
six patients (Buissert et al 1978). In two case reports, Lieb (1978, 1980) describes how
a dose of 975 mg acetylsalicylic acid removed milk- and coffee-induced
gastrointestinal symptoms.
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Nitric oxide is another mediator which has been connected with inflammatory
intestinal diseases. The substrate for the synthesis of this gaseous mediator is L-
arginine, and its formation is catalysed by nitric oxide synthases (NOS). It modifies
normal intestinal motility as described above as well as in an inflamed intestine such
as in cases of Crohn’s disease (Boughton-Smith et al 1993). The enhanced
production of nitric oxide has been found in inflammatory-induced tissues (see Stark
and Szurszewski 1992, Lefebvre 1995). The inducible form of NOS (iNOS) seems to
protect the intestine from inflammatory injuries (McCafferty et al 1997).
Prostaglandins and nitric oxide, both mediating the normal and inflamed motility of
the intestine, seem even to co-operate, at least in regulating the immune response to
injury (see Wallace 1996). The possible role of nitric oxide in lactose-induced
symptoms has not been studied, as far as we know.
To conclude, prostaglandins and nitric oxide mediate inflammatory responses in the
intestinal tract. The possible local intestinal inflammation caused by unhydrolysed
lactose, and the role of prostaglandins and nitric oxide in the development of
gastrointestinal symptoms, both need to be investigated in more detail.
Emotional factors
The connection between the severity of gastrointestinal symptoms experienced in
lactose intolerance and stressful life events has not been properly clarified. However,
symptoms related to the passage of food through the gastrointestinal tract, such as
abdominal pain and diarrhoea, are among the most commonly reported effects of
acute life stress in patients with irritable bowel syndrome (IBS) (see Stam et al 1997).
The symptoms of lactose intolerance resemble those of IBS, and on the basis of
symptoms alone it is difficult to distinguish between these two states.
Patients with IBS often have exaggerated responses of gut motility in the small
intestine (Camilleri et al 1989) and the colon (Fukudo et al 1993) in stressful
situations. Colonic motility has been shown to increase after a stressful test, both in
healthy controls and in IBS patients. Repeated tests, however, increased colonic
motility only in the IBS patients (Narducci et al 1985). Cognitive therapy studies
suggest that stress management procedures can alleviate the symptoms of IBS,
including diarrhoea (Camilleri et al 1989).
The possible role of stressful life events and the expression of a changed intestinal
motility pattern have been studied in healthy young men playing video games (Ditto
et al 1998). The experimental stress reduced intestinal mean transit time, measured
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by a lactulose breath hydrogen test, by about 25 min compared with a relaxed
situation. This was correlated with change in an index of cardiac sympathetic activity
(Ditto et al 1998). However, psychological stress in medical students during final
examinations did not change the orocecal transit time measured by an excretion of
lactulose breath hydrogen test (Harris and Martin 1994). Gastrointestinal symptoms
were also unchanged by the stress, except for abdominal pain, which increased. In
healthy subjects gastric antral motor activity recorded with real-time ultrasonography
was reduced by mental stress, but not in patients with functional dyspepsia who had
reduced motility at baseline (Hveem et al 1996).
It is possible that the responses of gastrointestinal motility may vary depending on the
stressor, as suggested by Rao et al (1998). They found that both psychological stress
induced by a dichotomous listening test and physiological stress induced by keeping
a hand in cold water enhanced colonic motor activity. Psychological stress affected
stool propulsion and colon transit, whereas in healthy humans physical stress was
associated more with delayed gut transit time (Rao et al 1998).
In experimental studies with dogs, acoustic stress for 1-2 h had no effect on fasting
jejunal MMC, but prolonged the pattern of irregular contractions after a meal (Gue
et al 1987, Gue et al 1989). When laboratory rats were partially or totally
immobilised (restraint stress) their motility patterns were changed both in a fasted
state and after a meal (Wittmann et al 1990). In the colon the changed motility
pattern continued for three days. In rats colonic motility seems to be a more sensitive
indicator of stress than the motility of the small intestine (Stam et al 1995).
Autonomic pathways are thought to mediate stress effects on intestinal transit and
motility (see Stam et al 1997), although responses are individual (Stam et al 1999).
To conclude, stressful stimuli modify visceral sensory and motor responses, a fact
which is based mainly on experimental studies and the studies of irritable bowel
disease. In IBS patients, stress increases the severity of gastrointestinal symptoms.
Even though the pathophysiology of lactose intolerance differs from that of IBS, the
symptoms do not, and thus it can be assumed that a stressful life also impairs, at least
to some extent, the gastrointestinal symptoms of lactose intolerance.
Drugs
Drugs which either deliberately or as an adverse-effect influence gastrointestinal
motility may also have an influence on the digestion and absorption of lactose.
Gastrointestinal prokinetics increase gut wall contractions, enhancing propulsive
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movements. They are used for the treatment of upper gastrointestinal disorders such
as gastro-oesophageal reflux disease (see Horn 1996, Tonini 1996). Metoclopramide
and cisapride are considered ‘old’ prokinetics. Metoclopramide has been used in the
treatment of vomiting of different etiologies and for a wide range of functional and
organic gastrointestinal disorders (see Koch-Weser 1981). Rather than having an
antagonist effect on dopamine D2 receptors, metoclopramide seems to act via 5-HT4
(serotonin) receptors, to stimulate gastric emptying and enhance lower oesophageal
sphincter pressure (see Tonini 1996). Cisapride is a serotonin (5-HT4) agonist,
enhancing the release of achetylcholine and thus increasing lower oesophageal
sphincter pressure and accelerating gastric emptying (see Horn 1996, Tonini 1996).
New prokinetic drugs are now being used in clinical studies. The 5-HT4 agonist
prucalopride (R093877) has been found to accelerate colonic transit (Bouras et al
1999). Erytromycin is a macrolide antibiotic which disturbs gastrointestinal motility
(see Alvarez-Elcoron and Enzler 1999). Its new structural analogues avoiding
antibacterial properties are classified as motilin agonists and have been tested for
inducing gastric contractions and reducing the motility of the small intestine (e.g.
Sarna et al 1991, Caron et al 1996).
Some other antibiotics, such as the amoxicillin-clavulanate combination, may also in
some cases disturb gastrointestinal motility, as shown by Caron et al (1991). Rather
than disturbing the normal intestinal microflora, Caron et al  speculated that this
changed motility was due to the release of an intraluminal mediator such as motilin
or to direct interaction with some aminobutyric receptors in the myenteric plexus. In
addition to these, motility effects have been reported with somatostatin analogues
(Dueno et al 1987, see Bueno et al 1997), the calcium channel blocker nifedipine
(Konrad-Dalhoff et al 1991), gastric acid suppressants ranitidine, famotidine,
nizatidine and omeprazole (see Bortolotti 1999), and the prostaglandin E2 analogue
enprostil (Nicholl et al 1989).
As an adverse effect, many drugs may induce constipation. These drugs include
agents from many categories such as analgesics, antacids (calcium and aluminium),
anticholinergics, antidepressants, antihypertensives, diuretics, iron preparations, and
neuroleptics (Tedesco et al 1985).
Laxatives enhance bowel movements by stimulating motility, retaining intraluminal
fluid by osmotic mechanism, or by increasing luminal contents. Recent studies have
shown that the pharmacological effects of some laxatives are mediated by
prostaglandin release, increased mucosal permeability, epithelial injury, and the
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increased release of nitric oxide (see Izzo et al 1998). In addition to interest in the
role of NO in the mechanisms of laxatives and in other effects of NO, a great deal of
attention has been paid to the investigation of NO and the inhibitors of its synthese
in regulating gut motility (see Tonini 1996). The inhibition of NOS may, however,
result in undesired side-effects because of the widespread targets of NO.
Antidiarrhoeal agents reduce the number of bowel movements and diminish fluid
loss. The most useful agents for slowing intestinal transit in acute diarrhoea are opiate
derivates such as loperamide, diphenoxylate and bismuth subsalicylate (see Aranda-
Michel and Giannella 1999). New peripherally-acting opiates such as fedotozine
have been developed and tested as antidiarrhoeal agents and for the treatment of
visceral hyperalgesia (Read et al 1997, Delvaux et al 1999).
Motility and sensory disturbances play an important role in the pathophysiology of
the symptoms of IBS. In fact, the drugs used to alleviate acute symptoms of IBS are
an overall collage of those agents affecting gut motility (see Bueno et al 1997,
Paterson et al 1999). Constipation may be relieved with laxatives and diarrhoea with
antidiarrhoeal agents. Attempts to resolve pain have been made by using drugs that
reduce gut spasm, such as anticholinergics and smooth muscle relaxants, or
prokinetics, to normalise the motility pattern of the intestine (see Paterson et al
1999), even if a clear relationship between symptoms and gastrointestinal motility has
not been demonstrated (see Klein 1988). Potential drugs for modifying visceral
hyperalgesia include opioid aginists (especially κ agonist fedotozine), serotonin
antagonists (5-HT3 and 5-HT4 receptor antagonists), and possibly somatostatin and
somatostatin analogues (see Farthing 1998). No medication has been shown to
alleviate abdominal bloating or distension (see Paterson et al 1999).
There is only one published study, as far as we know, that describes the influence of a
motility-affecting drug on the absorption of lactose. Lactose maldigesters were pre-
treated with 8 and 12 mg loperamide on different days and lactose absorption was
measured by using a breath hydrogen test (Szilagyi et al 1996). The loperamide-
induced prolongation of intestinal transit time by about 30 min improved tolerance
to lactose, as measured by reduced breath hydrogen concentration and diminished
gastrointestinal symptoms. These results should, however, be confirmed in a double-
blind placebo-controlled study.
To summarise, the primary cause for lactose intolerance, an unbalanced intake of
lactose in relation to the activity of lactase, cannot be treated, at least so far, with
motility-reducing or other drugs. Many drugs, however, have a prokinetic or
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antimotility action, and their use may either worsen or relieve the symptoms of
lactose intolerance.
2.4. Diagnosis of lactose maldigestion and related gastrointestinal
symptoms
A variety of methods has been used for diagnosing lactose maldigestion. Precise
standards do not exist. An intestinal biopsy is the only direct way of measuring lactase
activity. This cannot, however, be regarded as a standard test for measuring tolerance
to lactose, because mucosal lactase activity varies along the small intestine (Maiuri et
al 1992, Rossi et al 1997) and thus lactase activity in one biopsy, from a restricted part
of the small intestine, does not necessarily represent the total lactase activity of the
whole small intestine. There seem not to be consistent cut-off values for hypolactasia.
Varying activities between 5-18 U/g mucosal protein have been proposed (see
Brummer et al 1993). The measurement of lactase activities from a biopsy is
laborious, unpleasant for the patient, and can be performed only in hospitals.
In Finnish health care centres, measuring blood glucose concentration after an oral
load of 50 g lactose is the most commonly used method for testing tolerance to
lactose (Peuhkuri et al 2000a). At regular intervals, usually of 20 min, for up to 1-2
hours after the intake of a lactose solution, blood samples are taken and the glucose
concentration is determined. A dose of 50 g lactose (in small children 2 g/kg body
weight) is necessary for the blood test (see Arola 1994). Most laboratories regard a
glucose increase of less than 1.1 mmol/l as an indication of lactose maldigestion. The
test is simple to perform and the equipment needed is found in every clinical
laboratory. However, the sensitivity and specificity of the test have been questioned
because of the great inter-individual variations in gastric emptying and glucose
metabolism (see Newcomer et al 1975).
Some laboratories use a lactose tolerance test with ethanol to improve the sensitivity
of the test. Usually there are no measurable amounts of galactose in the blood or the
urine, because absorbed galactose has been quickly metabolised to glucose in the
liver (see Figure 2.3). In the tolerance test this change into glucose is inhibited with
ethanol (50-150 mg/kg), thus enabling the measurement of the galactose
concentration in the blood or the urine. 40 min after the ingestion of 50 g lactose,
one capillary blood sample is taken. A galactose concentration below 0.3 mmol/l is
considered an indication of lactose maldigestion (Isokoski et al 1972). Many scientists
have questioned the need to use ethanol for measuring galactose in the blood and
the urine in lactose tolerance tests, and modified methods without ethanol ingestion
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have been described (Arola 1988b, Grant et al 1989, Buttery and Ratnaike 1995). In
a recent study, in 3-hour pooled urine samples, the sensitivity of a lactose tolerance
test without ethanol was 100% and specificity was 94%, (Alvarez-Coca et al 1996).
The measurement of a breath hydrogen response after an oral load of lactose is based
on the principle that unhydrolysed lactose is fermented by the colonic microflora,
producing hydrogen and methane. Gases are diffused into the blood circulation and
excreted in expired air (Levitt 1969). A dose of 25 g (in children 1 g/kg body weight)
has recently been demonstrated as being sufficient in a breath hydrogen test (see
Hamilton 1998). This dose produces almost the same response in breath hydrogen
concentration as the larger dose of 50 g. The hydrogen concentration is analysed
either by gas chromatography or by an electrophysical sensor (Bartlett et al 1980).
Breath samples are taken at regular intervals of 30 min after the ingestion of lactose
until the hydrogen concentration exceeds the baseline value by at least 20 ppm,
indicating lactose maldigestion, or for up to three hours (see Hamilton 1998). A
recent study by Karcher et al (1999) suggested that a better cut-off value would be
10 ppm because the patients with only moderately increased hydrogen excretion (10-
20 ppm) may not be lactose deficient at all, as Karcher et al speculated.
The simultaneous measurements of breath methane may increase the reliability of a
tolerance test because some types of methanogenic bacteria in the colon convert
colonic hydrogen to methane. Bjørneklett and Jenssen (1982) found that 44% of 120
healthy subjects were methane producers. Thus, there seem to be hydrogen
producers, methane producers and those who produce both hydrogen and methane.
There do not seem to be even rough estimations of the number of pure methane
producers, i.e. the subjects who produce no hydrogen at all. If breath methane alone
is analysed, an increase of about 12 ppm is considered an indication of lactose
malabsorption without reference to the hydrogen response (see Hamilton 1998). The
breath methane test alone has lower sensitivity and specificity than the breath
hydrogen test and cannot replace the latter (Myo-Khin et al 1999).
The lactose breath hydrogen test is considered to be fairly reliable in detecting
lactose maldigestion (see Arola 1994, Hermans et al 1997, Hamilton 1998). There
are some factors that may possibly increase breath hydrogen excretion and may thus
reduce the reliability of the test, as reviewed by Arola (1994) and Hamilton (1998).
The influence of these factors is reduced when labelled lactose is used. After the
ingestion of 13C-labelled lactose (non-radioactive isotope), the digestion and
absorption of lactose can be detected as the cumulative concentration of labelled
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CO2 in the breath (Newcomer et al 1975, Hiele et al 1988, Vantrappen et al 1992).
Nowadays there is no risk of radiation, as there was in an earlier modification of the
use of a 14CO2-labelled malabsorption test (Salmon et al 1969, Sasaki et al 1970). In a
recent study by Koetse et al (1999), the sensitivity and specificity of a combined
13CO2/H2 breath test were 85% and 65% respectively.
The relationship varies between these tolerance tests and gastrointestinal symptoms.
There is a stronger association between the amount of hydrogen excreted and
gastrointestinal symptoms, whereas that between the increase in glucose
concentration and the symptoms of lactose is less evident (Newcomer et al 1975,
Hermans et al 1997, Teuri et al 1999). The blood glucose test is the most commonly
used in Finland (Peuhkuri et al 2000a).
2.5. Current methods of reducing lactose-related gastrointestinal
symptoms
It seems probable that the development of gastrointestinal symptoms caused by
maldigested lactose depends on the function of the whole gastrointestinal tract, not
just on the digestive and absorptive capacity of the upper small intestine.
Firstly, according to several studies, small doses of lactose, of up to 10-12 g, are
tolerated by many lactose maldigesters without gastrointestinal symptoms (Suarez et
al 1995, Vesa et al 1996). If a daily dose of lactose is divided into several small
portions, to be ingested throughout the day, the possibility of symptoms will decrease.
This will lead to an improved balance between the hydrolysing capacity of the
enzyme and the load of ingested lactose.
Secondly, other components of food ingested with lactose, as discussed above, delay
gastric emptying and intestinal motility, and this has been shown to improve
tolerance to lactose. If lactose is ingested in a reasonable quantity as a part of meal,
the possibility of symptoms, and/ or their severity, may decrease.
Thirdly, it may be possible in the future to reduce lactose-induced gastrointestinal
symptoms simply by supporting the function of the colon and its bacteria.
Finally, the possibility of secondary lactose intolerance, induced either by
gastrointestinal or other diseases or by their treatments, drugs, a stressful lifestyle or
any other factor, should not be overlooked.
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3. Aims of the study
The aim of this study was to clarify factors which may improve, pharmacologically or
otherwise, the digestibility of lactose in order to reduce lactose-induced
gastrointestinal symptoms.
More specifically, the present study had the following aims:
1. To prove the accuracy and usefulness of a simple, portable breath hydrogen
analyser (Micro H2) in oral lactose tolerance tests (I).
2. To evaluate whether the gastric emptying rate (II) or the temperature of the test
solution (III) affects the development of lactose-induced symptoms.
3. To investigate the possible role of acute inflammation and inflammatory
mediators, such as prostaglandins and nitric oxide, in the development of lactose-
induced symptoms (IV).
4. To assess whether, in an experimental model, lactase expression and activity are
inducible by dietary lactose in the intestinal epithelium (V).
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4. Subjects, study designs, materials and methods
4.1. Human studies (Studies I - IV)
4.1.1. Subjects and study designs
All the subjects were adult volunteers, aged from 18 to 66 years. They were recruited
mainly among the staff of the Institute of Biomedicine of the University of Helsinki,
Finland, and their families and friends. In Study I subjects were also recruited by a
local internet news group [rfc977] (puhe.terveys) which is mainly read by students
and staff from Helsinki University of Technology, and through announcements
among staff and students of the University of Helsinki. Additional subjects for Study
IV were recruited by inviting all those who had participated in previous lactose
intolerance studies (Vesa et al 1996, Teuri et al 1999) and had shown positive test
results, indicating hypolactasia.
In Study I the inclusion criteria were either diagnosed lactose intolerance or a strong
personal suspicion of it. Healthy subjects were invited as controls. All the volunteers,
lactose intolerants as well as healthy controls, followed the whole test procedure of
the oral lactose tolerance test. Of the volunteers in Studies II-IV, subjects were
included if they showed positive test results, indicating hypolactasia, in two out of
three lactose tolerance tests (the Golden Standard, see below). The tests used in
Studies I - IV are shown in Table 4.1. Ten volunteers were excluded because they
proved to be lactose digesters (II-IV). The final study group consisted of 72 subjects.
Some of them volunteered for more than one study, so the total number of subjects
in studies I-IV was 89 including those who withdrew or were excluded.
None of the subjects had received antibiotic (I-IV) or NSAIDs (IV) treatment during
the 2 weeks preceding the studies, and they did not use any medication during the
studies themselves. The subjects were interviewed by a physician, an authorized
nutritionist, or a laboratory nurse, and they filled in a health questionnaire. Only
those subjects who were seen to be healthy, with no recent history of gastrointestinal
disturbances other than lactose intolerance, were included.
The first human study (I) was carried out as a method comparison study comparing
two diagnostic instruments. The other human studies were carried out as
randomised, double-blinded (II, IV), three - (II - III) or four-period (IV) cross-over
trials with a 1-week wash-out period between the interventions. In each study in
identical sessions the subjects were given lemon-flavoured test solutions, either  50 g
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lactose or 50 g digestible disaccharide sucrose in order to compare the effects of the
two, in 300 ml water. The sampling sites for the biochemical measurements of the
lactose breakdown products and other biochemical indicators and the recording of
gastrointestinal symptoms were carried out according to the schedule of
measurements (Figure 4.1).
12    0             1              2               3               4 hU-gal
Gastrointestinal symptom questionnaire
Breath H2    x       x       x        x         x         x        x         x         x
fB-gluc       x    x     x    x     x     x     x     x      x     x     x      x     x
I
12    0             1              2               3                                       6                  9             12hU-gal
Gastrointestinal symptom questionnaire
Breath H2    x   x     x   x    x       x    x   x      x    x
fB-gluc       x   x     x   x    x       x    x    x      x    x
II
12    0             1              2               3                4                     6                 9            12hU-gal
Gastrointestinal symptom questionnaire
Breath H2    x    x     x   x     x       x    x    x      x    x      x     x      x
fB-gluc       x    x     x    x         x        x        x        x          x         x
III
12    0             1              2               3                 4                   6             8 hU-gal
Gastrointestinal symptom questionnaire
P-PG’s /U-PG’s /U-NOx                                  P-PG’s /U-PG’s /U-NOx                                            P-PG’s /U-PG’s /U-NOx
fB-gluc       x    x     x    x  IV
Figure 4.1. Schedule of measurements in each test session, Studies I-IV. There was a
one-week wash-out period each time before the next test session. Breath H2 = breath
hydrogen, fB-gluc = blood glucose, U-gal = urine collection for galactose measurement;
P-PG = plasma prostaglandin E2 metabolites; U-PG = urine prostaglandin E2
metabolites; U-NOx = urine nitric oxide metabolites.
Study I was designed to compare a small portable breath hydrogen analyser with the
more commonly used equipment, and to compare both these with other possible test
variables used in lactose tolerance tests.
41
In order to modify the gastric emptying rate (II), subjects ingested either
propantheline (as bromide, 15 mg), metoclopramide (as hydrochloride, 10 mg) or an
identical placebo (methylcellulose), all in capsule form an hour before the test
solution. The doses of these drugs were chosen on the basis of previous studies and of
the therapeutic single dose recommendation (Dollery 1991, Massicotte et al 1996).
In Study III, to investigate the role of the temperature of the test solution on the
digestibility of lactose and the subjects’ tolerance to it, the lactose was served either
cold (2-3o C), at room temperature (20-21o C), or hot (55-58o C).
In order to test the role of prostaglandins (IV), the subjects ingested either 600 mg
ibuprofen capsule to inhibit the synthesis of prostaglandins, or an identical placebo
(methylcellulose) capsule with the test solution. In Study IV, to test the role of nitric
oxide (NO), the subjects were on a low-nitrate diet for 48 h before the test days. All
the capsules used in Studies II and IV were identical apart from the active ingredient,
and were prepared at the University Pharmacy (University of Helsinki, Finland).
Table 4.1. Study designs and subjects.
Study I Study II Study III Study IV
Interventions to be
compared
Breath
hydrogen
analysers for
diagnosing
hypolactasia
L + propantheline
L + metoclopramide
L + placebo
L cold
L room-
temperature
L hot
L + ibuprofen
L + placebo
S + ibuprofen
S + placebo
Study design Method
comparison
Three-period
cross-over
Three-period
cross-over
Four-period
cross-over
Subjects (f/m) 34/10 18/0 10/0 9/0
Age, mean (range) years 32 (18-66) 34 (20-64) 39 (26-55) 38 (24-63)
BMI, mean (range)
kg/m2
23 (19-33) 23 (18-42) 25 (20-42) 22 (18-27)
Smokers  5/44 3/18 3/10 1/9
Lactose tolerance tests
used:
Breath hydrogen + + + -
Blood glucose + + + +
Urine galactose + + + +
Symptom questionnaire
(h)
4 12 12 8
L = Lactose, S = Sucrose, BMI = Body Mass Index
4.1.2. Dietary instructions and study diets
The subjects were instructed to choose lactose-free food items for the 24 h preceding
the test days (Studies I - III) and to avoid alcohol, smoking and foods that commonly
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produce gastrointestinal symptoms, such as beans, peas or fried foods, for the same
period in order to diminish gastrointestinal symptoms induced by foods other than
the test solution and to improve the reliability of the breath hydrogen measurements
(Brummer et al 1985). In Study IV, in addition to instructions for lactose restriction,
alcohol consumption and smoking, subjects were instructed to choose a low-nitrate
diet for 48 h preceding the test days in order to clear the plasma of exogenously
derived nitrate.
At fixed intervals from the beginning of the test procedure, the subjects in Studies II-
IV were served a standard lactose-free lunch (after 3 h), an afternoon snack (after 6 h)
and in Study II, dinner (after 9 h) (Table 4.2). In Studies III and IV the subjects were
instructed to choose dinner from a selection of lactose-free items. This type of meal
had been used previously in carbohydrate malabsorption studies (Rumensen et al
1990, Teuri et al 1999). Smoking was not allowed until the end of the test day, nor
were coffee, tea or any other food items other than those provided.
Table 4.2. Content of meals served during the Studies II - IV.
Food Study II Study III Study IV
Lunch 750 kcal (3.1 MJ)
minced meat + + +
spaghetti +
rice + carrots + +
wheat bread + margarine + + +
blueberry puree +
lettuce + canned peach + +
juice + + +
banana +
Afternoon snack 400 kcal (1.7 MJ)
wheat bread + margarine + + +
cheese + +
banana + juice + + +
decaffeinated coffee + +
Dinner 750 kcal (3.1 MJ)
minced meat + spaghetti + cheese +
tomato +
wheat bread + margarine +
banana + juice +
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4.1.3. Methods used for diagnosing hypolactasia and lactose intolerance
The Golden Standard diagnosis for hypolactasia and lactose intolerance (I-IV)
The lactose tolerance test was carried out by measuring the breakdown products of
lactose following an oral dose - increase in exhaled breath hydrogen, unaltered
concentration of blood glucose, increased excretion of urinary galactose - and the
development of gastrointestinal symptoms. Between 7 and 9 a.m, after an overnight
fast (10-12 h), the subjects were given 50 g lactose in 300 ml water, to be ingested in
5 min.
To avoid false positive or negative results in these studies, a Golden Standard
diagnosis was established for this series of studies. The Golden Standard is a
combination of the three diagnostic indicators: breath hydrogen, blood glucose and
urine galactose. At least two positive indicators were considered sufficient to indicate
hypolactasia. If lactose maldigestion was confirmed and gastrointestinal symptoms
were considered to be at least moderate, the subject was diagnosed as being lactose
intolerant.
Breath hydrogen measurement (I - III)
All the breath hydrogen measurements were carried out using a portable
electrochemical hydrogen analyser, Micro H2 (Micro Medical Limited, Chatman,
UK). Measurements were obtained by blowing (70 s) end-alveolar air, using 22 mm
mouthpieces. Breath measurements were carried out as shown in Figure 4.1. An
increase of ≥ 20 ppm was considered to be an indication of lactose maldigestion (see
Arola 1994). In Study I, as a reference analyser for hydrogen production in exhaled
air, the Quintron MicroLyzer, Model DP (Quintron Instrument Co. Inc.,
Milwaukee, WI, USA) was used.
Blood glucose and urine galactose measurements (I - IV)
All blood glucose concentration measurements were taken with the Glucometer
Elite (Bayer Diagnostics, Lungby, Denmark). Before each new lot, of blood strips the
equipment was auto-calibrated with a test strip of the new lot according to the
instructions of the manufacturer. The accuracy of this blood glucose test method has
been verified in earlier studies (Harrison et al 1996). Blood samples were aspirated
directly from a finger tip according to the study designs, as shown in Figure 4.1. An
increase in blood glucose concentration of 1.1 mmol/l or less was considered an
indication of lactose maldigestion (see Arola 1994).
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The subjects collected urine for the first three (I, II and IV) or four (III) hours, and
urinary galactose was assayed spectrophotometrically using a commercial enzyme kit.
If the 3- or 4-hour urinary galactose excretion was less than 20 mg, this was
considered to be an indicator of lactose maldigestion (see Arola 1994). This method
is considered to be a reliable, quantitative, non-invasive technique for assessing
profiles of ‘whole’ intestinal lactase activity (Bjarnason et al 1990).
Symptom questionnaires (I-IV)
The severity of gastrointestinal symptoms was assessed by the subjects themselves on a
scale of 0 to 10 (0 = no symptoms, 10 = severe symptoms) in a questionnaire which
was slightly modified from previously used models (Vesa et al 1996, Teuri et al
1999). The subjects filled this in at the baseline before the intervention, and every
60 min for the first three or four hours after the intake of lactose, and then at 6 h, 9 h
and 12 h (Figure 4.2). In Studies I and IV the recording of symptoms was completed
at the end of four and eight hours respectively from the ingestion of the test solution.
Pain None Only
slight
Fairly
severe
Moderate Severe
Baseline 0 1 2 3 4 5 6 7 8 9 10
1 h 0 1 2 3 4 5 6 7 8 9 10
2 h 0 1 2 3 4 5 6 7 8 9 10
3 h 0 1 2 3 4 5 6 7 8 9 10
4 h 0 1 2 3 4 5 6 7 8 9 10
5 - 6 h 0 1 2 3 4 5 6 7 8 9 10
7 - 9 h 0 1 2 3 4 5 6 7 8 9 10
10 - 12 h 0 1 2 3 4 5 6 7 8 9 10
Later, when? 0 1 2 3 4 5 6 7 8 9 10
Figure 4.2. An example of a numeric symptom questionnaire. Subjects were asked to
mark the presence and severity of symptoms hourly.
The subjects assessed the intensity of flatulence, abdominal pain, abdominal
bloating, borborygmi, nausea, headache, and the hardness of the stools. The sum of
the most common lactose-induced symptoms (see Villako and Maaroos 1994) -
flatulence, abdominal pain, abdominal bloating, borborygmi, and in Studies I and
IV, loose stools - was calculated for each time point. For the sum of four symptoms
the possible range was 0 to 40 and for the five symptoms the range was 0 to 50. If
each symptom was calculated individually for the 12 h follow-up, the maximum
score for each symptom would be 120. This long period of recording symptoms is
important because of individual variability in the time of gastric emptying and
intestinal transit and thus the development of gastrointestinal symptoms.
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In Study II, in order to evaluate the usefulness of the numerical grading of symptoms,
a visual analogue scale (VAS) (Figure 4.3) was used besides the numerical rating
scale to see whether there were differences between these two methods. At the
beginning of the test procedure subjects were given a numerical symptom
questionnaire to be filled in during the next 12 h. After each of the first four test
hours they were given another form, a new VAS questionnaire to be filled in, which
they returned as soon as they had done so. After Study II the results of these two
query methods were compared. The results did not differ. The 3-h symptom score
(flatulence, abdominal pain, abdominal bloating, borborygmi) of the placebo period
was 39.0 ± 4.7 in the numerical rating scale and 39.1 ± 4.6 in the VAS scale. The
subsequent work of measuring the results with the VAS questionnaire is very
laborious, and mainly for this reason the numerical rating scale questionnaire was
chosen.
No
 pain
Moderate pain Severe
pain
Figure 4.3. An example of the VAS symptom questionnaire for one time point.
4.1.4. Gastrointestinal transit time (II)
Gastrointestinal transit time was measured using a carmine dye mixed with the
lactose solution. The appearance of the dye was assessed visually in the stools by the
subjects themselves (Read et al 1980, Marlett et al 1981).
4.1.5. Urine and plasma samples for inflammatory markers (IV)
The subjects collected urine for the 12 h before the test and over the next eight
hours, divided into three aliquots for measurement of the excretions of prostaglandin
E2 and prostacyclin metabolites (PGE2 -M and 6-keto prostaglandin F1α respectively),
and indicators of nitric oxide production (nitrite and nitrate and cyclic GMP).
Venous blood samples for separating plasma were taken for prostaglandin E2
metabolite (PGE2 -M) measurements, before the drug and carbohydrate intake
(baseline) and 3 and 8 h after the baseline.
Plasma and urine levels of PGE2 metabolites were determined by using commercial
radioimmunoassay kits following the instructions of the company. For measuring the
indicators of nitric oxide production, nitrate was reduced to nitrite and determined
spectrophotometrically by a commercial test kit based on the Griess reaction. For the
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cyclic GMP determinations, as another indicator of nitric oxide production, the
urine samples were measured by radioimmunoassay as described by Axelsson et al
(1988). The cyclic GMP antiserum has been described by Lähteenmäki et al (1998).
4.2. Animal experiments (V)
4.2.1. Experimental animals and study design
Female Wistar rats from the breeding colonies of the Laboratory Animal Centre,
Helsinki University, Finland, were housed at 23o C with a light-dark cycle of 12 h.
Study V was designed to investigate the possibility that lactase protein expression and
its activity can be induced by lactose. The expression of lactase protein in the gut and
its possible induction was evaluated by immunohistochemical and biochemical
techniques in 8-week-old rats (total number 24, divided into four groups) after a
lactose challenge lasting seven days. The lactose-challenged rats received either 3%,
10% or 20% lactose-containing water or tap water (controls), ad libitum. The fluid
intake was measured daily by weighing the drinking bottles.
4.2.2. Intestinal samples
The animals fasted overnight before they were killed by decapitation under CO2
anaesthesia. Two-cm-long samples for determination of lactase activity and
expression were taken. Samples were from the proximal part of the stomach and the
oesophagus, the middle of the duodenum, the proximal, middle and distal parts of
the jejunum, and the proximal part of the ileum.
4.2.3. Biochemical determinations
Lactase activity
Lactase enzyme (EC 3.2.1.23) activity was assayed spectrophotometrically by the
method of Dahlqvist (1964). Lactase activity was expressed as units (one µmol of
lactose hydrolysed per minute at +37o C) per gram of total protein present in the
homogenates. The protein content of the homogenates was assayed by the method of
Lowry et al (1951).
Lactase expression by immunohistochemical methods
Paraformaldehyde (1%) fixed samples were immunoperoxidase labelled and
incubated with monoclonal antibodies raised against rat lactase. Optical density
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measurements were used in order to obtain a semi-quantitative measurement of
lactase protein expression.
4.3. Ethics
The designs of Studies I - IV were approved by the Ethical Committee of the
Institute of Biomedicine, University of Helsinki, Finland. The design of Study V was
approved by the Animal Experimentation Committee of the Institute of
Biomedicine, University of Helsinki, Finland. Studies II and IV were also approved
by the National Agency for Medicine, Finland.
4.4. Statistical analyses
In Study I, which was to compare the portable breath hydrogen analyser, the method
of Bland and Altman (1986) was used to assess the agreement between the two breath
hydrogen tests (Micro H2 vs Quintron).
In Study II, a mixed-effect ANOVA model was used to analyse the sum of symptom
scores. Pair-wise post hoc analyses were carried out using repeated measures contrast
analysis. The distributions of the symptom scores of individual symptoms in Studies
II and III and the urine and the plasma variables in Study IV were skewed.
Friedman’s nonparametric analysis of variance was therefore applied to compare the
differences between the interventions. The Wilcoxon matched pairs test was used for
pairwise comparisons. In Study II, Spearman’s rho correlation was calculated
between the total transit time and gastrointestinal symptoms.
In Study V, statistical significance was determined by analysis of variance (ANOVA),
and multiple comparisons were made by the Dunnet’s post hoc test.
Sensitivity, specificity, and positive and negative predictive values were calculated to
evaluate the breath hydrogen, blood glucose and urine galactose as diagnostic
variables. The comparisons were made with the Golden Standard. Cohen’s Kappa
values and percentages of agreement were calculated to evaluate the agreement
between any two diagnostic variables.
Results are expressed as Mean ± SEM, as Mean (range) or as percentage and
95 % CI. All statistical analyses were carried out using the SPSS statistical package
(Release 7.5.1 / 8.0, SPSS Inc., Chicago, IL, USA).
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5. Results
5.1. Comparison of diagnostic methods for detecting lactose
maldigesters
The final number of participants in Studies I-IV was 72. Overall, there were 89, but
some of the subjects volunteered for more than one study and 10 withdrew or were
excluded for various reasons.
Of the 72 participants 42 had previously been diagnosed as being lactose intolerant.
These diagnoses were made by official health professionals, or else the subjects were
diagnosed in earlier lactose intolerance studies by our group (Vesa et al 1996, Teuri
et al 1999). Thirty were self-diagnosed lactose intolerants. A third of the previously
diagnosed and two thirds of the self-diagnosed subjects proved to be lactose digesters
according to the Golden Standard diagnosis (see Chapter 4) (Figure 5.1). About one
tenth (4/38) of the maldigesters were asymptomatic and about 20% (7/34) of the
digesters were symptomatic according to the oral lactose tolerance test (Figure 5.1).
Symptoms
28
No symptoms
2
Symptoms
5
No symptoms
7
Symptoms
6
No symptoms
2
Symptoms
2
No symptoms
20
Subjects who considered themselves to be lactose intolerant
72
Previously diagnosed 
lactose intolerants
42
Self-diagnosed 
lactose intolerants
30
Maldigesters*
30
Digesters
 12
Maldigesters*
8
Digesters
 22
* Positive findings for at least two of the three variables (breath hydrogen, blood glucose, or urine
galactose excretion)
Figure 5.1. Studies I-IV. Distribution of previously diagnosed lactose intolerant and
self-diagnosed lactose intolerant subjects, according to laboratory findings and
symptoms (symptom score ≥ 12 / 3-4 h), after ingestion of 50 g lactose.
In Study I, in order to test the usefulness of the portable breath hydrogen analyser
Micro H2, altered breath hydrogen concentration was measured with the two
analysers, the Micro H2 and the Quintron MicroLyzer. Even though the highest
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increase in the exhaled breath hydrogen over the baseline varied greatly (44-366 ppm
for Micro H2 and 27-187 ppm for Quintron MicroLyzer), the diagnoses were 100%
identical. Since the Micro H2 proved to be reliable for detecting lactose
malabsorption, all the data of breath hydrogen concentrations presented here is
measurements taken with the Micro H2.
In addition to proving the usefulness of the Micro H2 breath hydrogen analyser, the
data of Study I made it possible to compare the three diagnostic variables (breath
hydrogen, blood glucose and urine galactose) for detecting lactose maldigesters. In
order to increase the number of subjects the comparison of the test variables was re-
made with subjects participating in Studies I-III. Each subject is considered once
only, even if she participated in more than one study. If this was the case, the first
study in which she participated was chosen for this comparison. In the end the final
number of subjects in Studies I-III was 70, of whom 35 proved to be lactose
maldigesters according to the Golden Standard.
When these three variables for diagnosing hypolactasia were compared, none of
them alone recognised all the maldigesters or all the digesters (Table 5.1). The
number of misdiagnosed maldigesters was most obvious if the blood glucose test was
used on its own (3/35), and the largest number of lactose digesters (5/35) was
misdiagnosed by the urine galactose test (Table 5.1). The sensitivity (the ability of the
test to recognise lactose maldigesters) of the breath hydrogen test was 94% (33/35), of
the blood glucose test, 91%, (32/35), and the urine galactose test, 97% (34/35)
(Table 5.2). The specificity of the tests (the ability to recognise lactose digesters), was
94%, 91%, and 86% respectively (Table 5.2).
Table 5.1. Studies I-III. Combination of results of breath hydrogen, blood glucose, and
urine galactose for detecting lactose maldigesters (LM according to the Golden
Standard).
Breath hydrogen fB-glucose Urine galactose
Positive*** Negative Total
Positive* Positive** 29LM 1 LM 30
Negative 3 LM 2 5
Total 32 3 35
fB-glucose
Negative Positive 2 LM 3 5
Negative 5 25 30
Total 7 28 35
Positive if * ≥ 20 ppm ** increase  ≤ 1.1 mmol/l ***  ≤  20 mg/3-4 h
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Table 5.2. Studies I-III. Diagnostic characteristics of breath hydrogen, blood glucose,
urine galactose tests, and symptoms (symptom score ≥ 12 / 4 h) compared with the
Golden Standard. n=70.
Breath hydrogen fB-glucose Urinary galactose Symptoms
Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI
Sensitivity 94 88–100 91 84–100 97 93–100 89 82–98
Specificity 94 88–100 91 84–100 86 78–96 77 67–89
Positive
predictive value
94 88–100 91 84–100 87 79–97 79 69–91
Negative
predictive value
94 88–100 91 84–100 97 93–100 87 79–97
Sensitivity (%) =[true positives /(true positives + false positives)]× 100
Specificity (%) = [true negatives/(true negatives + false negatives)]× 100
Positive predictive value (%) = [true positives/(true positives + false positives)]× 100
Negative predictive value (%) = [true negatives/(true negatives + false negatives)]× 100
The percentages of agreement and Cohen’s kappa for the combination of breath
hydrogen, blood glucose and urine galactose tests and gastrointestinal symptoms can
be seen in Table 5.3. Differences between the test pairs were small and no statistical
significances were found. Thus, none of the combinations is superior for detecting
lactose maldigestion.
Table 5.3. Studies I-III. Percentages of agreement and Cohen’s kappa for the pairwise
comparisons of breath hydrogen (H2), blood glucose (fB-gluc) and urine galactose (U-
gal) and gastrointestinal symptoms (symptom score ≥ 12 / 4 h). n=70.
Percentage of agreement Cohen’s kappa
% 95% CI κ 95% CI
H2 vs fB-gluc 86 78–96 0.71 0.55–0.88
U-gal 86 78–96 0.71 0.55–0.88
Symptoms 83 74–94 0.66 0.48–0.83
fB-gluc vs U-gal 83 74–94 0.66 0.48–0.835
Symptoms 77 67–89 0.54 0.35–0.74
U-gal vs Symptoms 77 67–89 0.54 0.34–0.74
The diagnostic limit for a clinically significant symptom score was ≥ 12. The
sensitivity, specificity, positive predictive value, and negative predictive value of the
symptom questionnaire in Studies I-III can be seen in Table 5.2. The best percentage
of agreement with Cohen’s kappa for gastrointestinal symptoms and a positive test
variable was with the breath hydrogen test (Table 5.3). Of the maldigesters, 83%
(31/35) with a positive breath hydrogen test had an increased symptom score. On the
other hand, about 20% of the lactose digesters with negative breath hydrogen had
significantly increased symptoms. The percentage of agreement of the symptoms and
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both the blood glucose and the urine galactose tests was 77% (95% CI 67 to 89) and
Cohen’s kappa for both these was 0.54 (Table 5.3).
In Studies II and IV there was a health questionnaire in which the subjects answered
questions about gastrointestinal symptoms and their correlation to milk and dairy
products (unpublished data). These questions were answered before the test and the
diagnosis of lactose intolerance. Both the lactose maldigesters and the digesters
experienced flatulence as the most uncomfortable gastrointestinal symptom
(Table 5.4). In the oral lactose tolerance test after 50 g lactose, 1/27 of these
maldigesters was asymptomatic whereas 4/7 of the lactose digesters were symptomatic
with at least a 12-point symptom score.
Table 5.4. Studies II and IV. Gastrointestinal symptoms that were reported as the most
uncomfortable, i.e. number of subjects reporting the order of discomfort, by lactose
maldigesters (n=28) and digesters (n=7).
Great discomfort Some or slight discomfort No discomfort
Maldigesters
Flatulence 18 10 0
Abdominal bloating 10 16 1
Abdominal pain 17 7 3
Diarrhoea 8 10 9
Constipation 3 11 7
Digesters
Flatulence 4 2 1
Abdominal bloating 3 2 2
Abdominal pain 1 4 1
Diarrhoea 1 4 2
Constipation 2 4 2
5.2. Modification of gastric emptying and the temperature of the
test solution
In Study II gastric emptying was retarded with a single oral dose of propantheline (as
bromide, 15 mg) and speeded up with metoclopramide (as hydrochloride, 10 mg).
The most obvious result of modified gastric emptying was the diminishing of
gastrointestinal symptoms after the ingestion of propantheline (Figure 5.2). The
symptom score (flatulence + borborygmi + abdominal bloating + abdominal pain)
was significantly reduced by propantheline compared to the metoclopramide, after
1 h and 2 h, or compared to the placebo after 6 h and 9 h (Figure 5.2). The
acceleration of gastric emptying by metoclopramide did not affect the symptom score
(Figure 5.2) or any single symptom (Table 5.5) compared with the placebo.
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Figure 5.2. Study II. Gastrointestinal symptom scores of lactose maldigesters after an
oral lactose dose with either propantheline (as bromide, 15 mg) ( ), metoclopramide
(as hydrochloride, 10 mg) () or a placebo (). Results are expressed as mean
± SEM, n=18. * p<0.05 propantheline compared with the placebo, # p<0.05
propantheline compared with metoclopramide.
The nature of lactose-induced gastrointestinal symptoms can be clearly seen in
Figure 5.2. During an oral lactose tolerance test it takes a few hours for clinically
significant symptoms to develop. Symptoms last several hours and their severity
diminishes more slowly than it takes to develop, making the symptom curve skew to
the right. Except in the case of abdominal bloating, the same shape as the overall
symptoms curve can be seen in each individual symptom. With abdominal bloating,
regardless of the intervention, reduction in the severity of the bloating was much
slower than in any other symptom.
The 12-h sum of symptom scores for flatulence, borborygmi, abdominal bloating and
pain can be seen in Table 5.5. Propantheline reduced abdominal bloating compared
to the placebo. Compared to metoclopramide, propantheline reduced both
abdominal bloating and abdominal pain.
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Table 5.5. Study II. The 12-h sum of symptom scores of flatulence, borborygmi,
abdominal bloating and abdominal pain, during the 12 h follow-up in lactose
maldigesters after oral ingestion of 50 g lactose with either propantheline (as bromide,
15 mg), metoclopramide (as hydrochloride, 10 mg) or a placebo. Mean (min to max),
n=18.
12-h Symptom scores Placebo Propantheline Metoclopramide Friedman
p-value1
Flatulence 29 (6 to 51) 25 (6 to 52) 29 (10 to 55) 0.09
Borborygmi 21 (0 to 51) 17 (4 to 45) 20 (0 to 51) 0.16
Abdominal bloating 22 (0 to 53) 16 (0 to 51) P, M 21 (0 to 44) 0.02
Abdominal pain 14 (0 to 37) 11 (0 to 44) M 14 (0 to 40) 0.19
1 Significance of treatment effect in a non-parametric Friedman analysis
M p<0.05 compared to metoclopramide
P p<0.05 compared to the placebo
The retarding of gastric emptying did not modify the total gastrointestinal transit time
as measured with carmine dye. Transit time varied greatly (1.5 h - 72 h) independent
of the treatment, because of large interindividual variations. There was no correlation
between transit time and the development of gastrointestinal symptoms following the
ingestion of lactose. Spearman’s rho correlation values were very near zero, varying
between -0.11 and 0.22.
In Study III the temperature of the lactose solution affected each of the symptoms
differently. Due to these fluctuations, the symptom score of flatulence + borborygmi
+ abdominal bloating + abdominal pain was of little use in estimating the effect of
the test solutions. The effects of a cold test solution were more intense than the
effects of a hot solution, compared with the room temperature solution. The cold test
solution tended to increase abdominal pain (p=0.09) and reduced flatulence and
bloating compared with the room temperature solution, expressed as the 12-hour
symptom scores (Table 5.6).
Table 5.6. Study III. The sum of symptom scores of flatulence, borborygmi, abdominal
bloating and pain during the 12-h follow-up in lactose maldigesters after a room
temperature, a cold  and a hot solution of 50 g lactose. Mean (min to max), n=10.
12 -h Symptom scores Room temperature
21-22o C
Cold
2-3o C
Hot
55-58o C
Friedman
p-value1
Flatulence 31 (20 to 44) 24 (7 to 38) R 31 (10 to 52) 0.01
Borborygmi 19 (1 to 35) 19 (0 to 32) 20 (3 to 38) 0.25
Abdominal bloating 27 (17 to 34) 23 (8 to 32) R 30 (11 to 42) 0.02
Abdominal pain 12 (0 to 30) 18 (0 to 33) 17 (5 to 39) 0.08
1 Significance of treatment effect in a non-parametric Friedman analysis
R p<0.05 compared to the room temperature test solution
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5.3. Measurement of inflammatory markers following the ingestion
of lactose
The purpose of Study IV was to investigate the possible role of inflammation in
provoking gastrointestinal symptoms following the ingestion of lactose. The
enhanced or reduced production of prostaglandins as a signal for possible
inflammation were measured as urine and plasma PGE2-M excretions. The synthesis
of prostaglandins via inducible COX-2 increases with inflammation. In the urinary
excretion of PGE2-M an increase of about 30% in the excretion was noticed after the
lactose intake compared with the sucrose intake (Figure 5.3). Ibubrofen tended to
inhibit this increase. The same increase and its inhibition by ibuprofen was also seen
with the urinary excretion of another metabolite of prostaglandins, 6-keto-
prostaglandin F1α, but with both these variables, PGE2-M and 6-keto PGF1α,
interindividual variation was considerable and no statistically significant differences
in the inhibition by ibuprofen were remarked (Figure 5.3). In the plasma PGE2-M
excretion there were no differences between the lactose and the sucrose intakes, with
or without ibuprofen.
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Figure 5.3. Study IV. Excretion of the prostaglandin metabolites PGE2-M and 6-keto
PGF1α  in the urine during the 8-h collection in 3-h, 6-h and 8-h aliquots, in lactose
maldigesters (n=9) after an oral lactose (L) or sucrose (S) solution with either oral
ibuprofen (I) or a placebo (P). Mean + SEM.  = 3 h sample,  = 6 h sample, and
 = 8 h sample.
In no other indicators of inflammation that were used - e.g. nitric oxide production
measured as the urinary excretion of cyclic GMP and NOx , and blood leukocyte
count (unpublished data, Table 5.7) - were any differences seen between the lactose
and the sucrose intake, with or without ibuprofen.
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Table 5.7. Study IV. Blood leukocyte counts (×  109 / l) in four lactose maldigesters
before and after a lactose tolerance test, with and without a single oral dose of
ibuprofen.
Subject n:o Lactose + Placebo Lactose + Ibuprofen
Baseline 3 h 8 h Baseline 3 h 8 h
4 3.2 4.5 3.8 3.0 3.6 4.9
5 5.1 4.5 5.2 5.9 5.6 7.7
7 6.0 5.8 6.1 6.4 6.2 7.1
10 9.4 8.2 9.7 10.7 10.1 10.9
5.4. Induction of lactase with lactose
In Study V the dietary modification of lactase enzyme activity was investigated in the
rat intestine. Lactase activity was found only in the small intestine, with the
exception of  those rats that received the largest doses of lactose. In these, it also
appeared in the colon. There was no activity present, measured
spectrophotometrically, in the oesophagus, the stomach or in the colon of the control
animals or those who received the smallest doses of lactose. Water intake and weight
gain during the study period can be seen in Table 5.8.
Table 5.8. Study V. The effect of a seven-day supplementation of lactose on weight
gain and daily water intake. Mean ± SEM, n=5-6.
Lactose g/day
0 0.7 2.1 2.6
Weight gain (g/week) 44.3 ± 5.4 20.2 ± 5.4* 18.2 ± 7.3* 23.8 ± 7.9*
Water intake (ml/rat/day) 32.4 ± 0.7 23.3 ± 2.1 20.6 ± 2.6* 12.7 ± 1.5**
*p<0.05, **p<0.001 ANOVA with Dunnett’s multiple comparison test (control vs test group)
The optical density of lactase immunoreactivity was measured from the proximal part
of the jejunum. In the control animals this was 0.19 ± 0.01 arbitrary units. It
increased 25-40% in the lactose supplemented groups. Dietary lactose increased the
activity of lactase, especially in the proximal (p=0.01) and middle parts of the
jejunum (p=0.02). If the total lactase activity of the control group, measured by
combining the activities of five small intestinal biopsies, is 100%, a lactose
supplementation of 10-12 g/kg body weight/day increased this activity by about 40%
(Figure 5.4).
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Figure 5.4. Study V. The effect of a seven-day supplementation of lactose on lactase
activity in the rat, expressed as a percentage of the control group (control group
=100%).  = duodenum, = proximal jejunum,  = middle jejunum,  = distal
jejunum,  = ileum. *p<0.05 ANOVA with Dunnett’s multiple comparison test
(control vs. test group). n=5-6 animals/group.
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6. Discussion
6.1. Evaluation of study designs and methods
6.1.1. Human studies
In this series of studies the purpose was to investigate the possible mechanisms
affecting the digestion of lactose, as well as the gastrointestinal symptoms induced by
undigested lactose. Side by side with this, the prevalent methods for diagnosing
hypolactasia and lactose intolerance came under scrutiny. Lactose maldigestion is
usually identified by means of an oral lactose tolerance test, in which, following
ingestion of 50 g lactose, maldigestion is detected either by a reduction in the
increase of an unabsorbed breakdown monosaccharide component of lactose
(glucose or galactose) in either the blood or the urine concentration, or by an
increase of hydrogen produced by the colonic fermentation of malabsorbed lactose
(see Arola 1994).
Great care was taken to minimise all those factors known to affect test variables for
detecting hypolactasia. In this we were enormously supported by the extremely co-
operative study subjects, all of whom were healthy volunteers. Pre-test restrictions
such as the limited use of medication and a controlled diet before and during the test
were imposed in order to improve the comparability of the study periods. It is just
possible, however, that the avoidance of coffee among coffee drinkers and smoking
among smokers may have influenced the symptoms recorded during the test.
Fortunately, rather than affecting gastrointestinal symptoms, coffee withdrawal is
probably more likely to result in headache and overall discomfort, and there was only
a relatively small number of smokers.
Studies were, whenever possible, randomised (II-IV), double-blinded (II, IV) and
cross-overed (II-IV). The evaluation of the usefulness of the Micro H2 breath
hydrogen analyser for detecting hypolactasia (Study I) was not blinded. The analyser
proved to be reliable for this purpose compared with the stable hydrogen
measurement unit Quintron MicroLyzer or with the Golden Standard. To compare
its ability to measure breath hydrogen concentration, it might also have been possible
to measure exhaled hydrogen after another undigestible carbohydrate such as
lactulose, as we did in a previous study (Teuri et al 1999). This combination
lactose/lactulose breath hydrogen test enables one to calculate lactose malabsorption
by comparing areas under the curves of the lactulose breath test (100% malabsorbed)
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and the lactose breath test. It also enables the measurement of intestinal transit time
(Hammer et al 1996).
However, more experiments are needed to standardise the collection of exhaled
hydrogen for analysis with the Micro H2 analyser. In this study the collection of
hydrogen was controlled by strictly limiting the collection time to 70 s and inhibiting
the passage of hydrogen through the nose by using a nose clip, as advised by the
manufacturer of the equipment. However, even though the subjects were allowed to
exhale slowly through the mouthpiece of the Micro H2 analyser, methods of blowing
varied. This possible bias in the inter-individual comparison of results was minimised
by using cross-over study designs when no comparison between the subjects was
needed.
The total number of study periods in each study was kept to the minimum. This was
because of the perennial difficulty in getting lactose maldigesters to participate in a
study in which they will have to ingest several large doses of lactose, after which they
know, or assume, that they will suffer severe gastrointestinal symptoms. Based on
experience from earlier studies, women are more willing to take part in studies such
as these than men. It was thought that it would be better to investigate single-sex
groups in order to make the study group more homogeneous. General conclusions
based on very homogeneous groups should, however, be drawn with circumspection.
There are relatively few reports describing the possible differences in the tolerance of
lactose between men and women. Hypolactasia is equally prevalent in both sexes
(Sahi 1974b), though female lactose maldigesters seem to be more sensitive to lactose
than men (Vesa et al 1998) despite the fact that the amount of malabsorbed lactose
measured by the breath hydrogen test is similar in both sexes (Krause et al 1997).
The influence of gender and the menstrual cycle on gastric emptying and
gastrointestinal transit has not been clearly demonstrated. Several studies have found
gastric emptying to be faster in men than in women (Datz et al 1987, Hutson et al
1989, Degen and Philips 1996, Hermansson and Sivertsson 1996, Knight et al 1997),
whereas others found little or no difference (Horowitz et al 1985, Saltzberg et al
1988, Madsen 1992). In a recent study, evidence of the postprandial reduction of
gastric emptying was found in women, but no differences between men and women
during fasting were observed (Caballero-Plasencia et al 1999). The phases of the
menstrual cycle, however, have not been reported as modifying the gastric emptying
of solids or liquids (Caballero-Plasencia et al 1999), but Wald et al (1981) reported
that the whole gastrointestinal transit was reduced by 25% during the luteal phase
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compared with the follicular phase. The interesting questions of gender or phases of
the menstrual cycle on gastrointestinal transit cannot be answered by our present
studies: we were restricted to one gender and the phases of menstrual cycle were not
recorded.
The symptom questionnaire we used was based on the questionnaires used
previously by us in grading gastrointestinal symptoms in lactose intolerance studies
(Vesa et al 1996, Teuri et al 1999). This type of questionnaire has not yet been
statistically validated in recording lactose-induced gastrointestinal symptoms but has
been successfully used by us with almost two hundred lactose intolerant subjects. We
also compared the numerical grading of symptoms with a visual analogue scaling
(VAS). Since no differences in symptom scores were found between these two
grading methods, the numerical grading was chosen, mainly because of the more
straightforward analysis of results.
6.1.2. Experimental studies
Using experimental animals as a model for investigating hypolactasia provides a
valuable tool for detecting mechanisms behind the regulation of the expression and
activity of lactase. Even though rodents and humans differ in many ways, the basics
of the normal physiological pattern of the lactase enzyme are similar. Thus it makes
sense to use the rat as an experimental model for studying hypolactasia. Both human
beings and the rat have a high expression of lactase in sucklings, after which the
expression and activity both decline to the lower level of adulthood. The time period
of this decline differs. In rats the decline begins soon after weaning, as shown by us
and others (Büller et al 1989), and in humans, later in childhood (Sahi et al 1972).
However, this is a minor difference when adult animals are used, as they were in this
study.
Since we wanted to investigate the effect of a lactose supplementation on low adult
levels of lactase, the animals we used were 8-9 weeks old. At this age, the level of
lactase was already significantly reduced. The lactose content of the milk of nursing
rats varies between 1 and 3.5%, depending on the age of the sucklings (Kuhn 1972).
The lowest concentration for supplementation, which was 3%, was chosen to imitate
this level of lactose in the milk of nursing rats. Two significantly higher
concentrations, 10% and 20%, were also used, in order to see clearly the possible
dose dependency in the induction of the lactase enzyme.
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Water intake and weight gain were reduced by 50-60% in those animals who
received large doses of lactose mixed with water. The intake of the lactose-water
solution and the overall well-being of the animals were recorded daily. It is possible
that the rats disliked the sweet taste of the lactose and thus drank less. Nor can the
other possibility of increased gastrointestinal discomfort by maldigested lactose be
excluded. No signs of diarrhoea, however, were noticed. It would be interesting, in
an experimental hypolactasia model, to have a suitable piece of equipment for
recording the gastrointestinal discomfort of the rat, even though experimental models
are for investigating the mechanisms, not the symptoms, of lactose maldigestion.
6.2. Possible tools for reducing lactose-induced gastrointestinal
symptoms
6.2.1. The hypothesis of the role of gastric emptying and intestinal motility
Reduced gastric emptying and total gastrointestinal transit time are thought to
increase mucosal contact time and thus to reduce the quantities of unabsorbed
lactose in the colon. In addition to this hypothesis, reduced intestinal motility may
also affect the colonic flora and thus modify fermentation products, as suggested by
El Oufir et al (1996) and Lewis and Heaton (1997). This may also improve tolerance
to lactose.
We found that by inhibiting peripheral muscarinic receptors with an oral dose of
propantheline, tolerance to lactose, measured as the severity of gastrointestinal
symptoms, improved. It is possible that reduced symptoms in our study after
propantheline could, at least partly, be due to the non-specific antispasmodic effect
of propantheline. However, in addition to reduced gastrointestinal symptoms, the
reduced excretion of breath hydrogen and the increased excretion of urine galactose
indicate better absorption of lactose. Among other anticholinergic and antispasmodic
properties, propantheline has been shown effectively to delay gastric emptying
(Hurwitz et al 1977).
Apart from the slight tendency of an earlier appearance of gastrointestinal symptoms,
we found no differences in tolerance to lactose after pre-treatment with the
prokinetic agent metoclopramide as compared with the placebo. A minor indication
of lesser absorption of lactose was seen with an increase in the excretion of breath
hydrogen and in the reduced excretion of urine galactose. Gastric emptying of a
lactose solution after an overnight fast might be fairly rapid even without a small dose
of metoclopramide. Perhaps the dose we used, which was chosen on the basis of
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previous studies (Massicotte et al 1996) and of the average therapeutic single dose
recommendations (Dollery 1991), was not sufficient for all our subjects.
Even though we found no correlation between the total gastrointestinal transit time
and the development of gastrointestinal symptoms, the possibility cannot be excluded
that the reduction of gastric emptying also modified intestinal motility. In another
study, the anti-diarrhoeal drug loperamide reduced intestinal transit in lactose
maldigesters by about 30 min (Szilagyi et al 1996). This prolongation has been found
not only to diminish but also to some extent to delay the development of
gastrointestinal symptoms (Szilagyi et al 1996), but we were not able to confirm this.
Carmine dye and the subjective estimation of its appearance in the faeces may not
have been a sufficiently sensitive way to detect gastric emptying reduction. This
method for measuring gastrointestinal transit time was chosen because it is
considered a fairly simple, cheap and reliable method (Read et al 1980, Marlett et al
1981) and was readily accepted by the study subjects. Even though there may have
been little value in this method of measuring transit time, it may have increased the
compliance of the study subjects since it is a good, and at the same time objective,
means which can be observed by them personally. There are more exact methods for
measuring gastric emptying, such as the radioscintigraphic technique, the 14C
octanoic acid breath test, and the use of ultrasonography or radiopaque capsules, but
since these methods are unsuitable for out-patients or need special equipment, a
greater number of study periods or the collection of faeces over a long period, the
estimation of transit time with dye was chosen.
We thus proved with a simple design, without the affecting factors of any other diet
or milk components, that by retarding gastric emptying, tolerance to pure lactose was
improved. This confirms previous observations of diminished symptoms after
retarding gastric emptying by dietary modifications (Welsh and Hall 1977, Nguyen et
al 1982, Solomons et al 1985, Martini and Savaiano 1988, Marteau et al 1990, Mahe
et al 1994, Dehkordi et al 1995, Vesa et al 1997a, Vesa et al 1997b).
6.2.2. The hypothesis of inflammation
In order to investigate the possible role of inflammation in the symptoms of lactose
intolerance, we compared the effects of lactose with a digestible disaccharide,
sucrose. The synthesis of prostaglandins, as a marker of inflammation, was reduced
by administering ibuprofen at the same time as lactose. Prostaglandins are
synthesised via the cyclo-oxygenase pathway (COX) in response to stimuli which, in
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the gut, include such things as mechanical stimulation, cell trauma and
inflammation (see Hawkey and Rampton 1985). Ibuprofen is a nonselective COX
inhibitor, affecting both constitutive COX-1 and inducible COX-2.
In the urinary excretion of the prostaglandin metabolites PGE2-M and 6-keto
prostaglandin F1α, an increase of about one third was noticed between the lactose and
the sucrose intakes. By reducing the synthesis of prostaglanins by inhibiting the COX
pathway with ibuprofen, this difference between a purely lactose intake and lactose
ingested with ibuprofen was not eliminated. Nor were any differences seen in the
plasma PGE2-M excretion. On the other hand, gastrointestinal symptoms and their
severity increased after ibuprofen, both with lactose and with sucrose. Thus it seems
probable that gastrointestinal symptoms after ibuprofen are not related to lactose
ingestion but rather to COX1 inhibition, and thus they cannot be abolished by
reducing the synthesis of prostaglandins, even though slight changes in the excreted
concentrations of prostaglandin were noticed.
Hence our findings do not support the hypothesis that lactose-induced symptoms are
related to an increased production of prostaglandins, as suggested previously by
Buissert et al (1978), Lieb (1978) and Lieb (1980). In agreement with Flatz and Lie
(1982) we found no relief in gastrointestinal symptoms after the inhibition of
prostaglandin synthesis. Thus the role of prostaglandins in mediating the symptoms
of lactose intolerance is minor, if it exists at all.
To test the role of another possible marker of intestinal inflammation, the enhanced
production of nitric oxide, we measured the concentrations of its excreted
metabolites after a lactose challenge. To our knowledge, no previous studies of the
role of NO in lactose intolerance exist. In this study the effect of exogenous nitrate
was reduced by restricting the dietary intake of nitrate for 48 h preceding the test, as
suggested by Wennmalm (1995). In the excretions of the urinary concentrations of
nitrate + nitrite (NOx), which is a stable metabolite of NO, and cyclic GMP, which is
a second messenger of NO, no differences related to lactose ingestion were found.
A new method has been recently introduced to measure by chemiluminescence the
luminal concentrations of gaseous NO from rectal gas samples, with no need for
colonoscopy (Herulf et al 1999). In gastro-enteritis patients, rectal NO measurements
taken this way were a hundred times higher than in the healthy controls (Herulf et al
1999). This method could also perhaps be a new means of investigating the possible
role of NO in lactose intolerance. However, when measuring excreted metabolites,
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there is always the problem of whether the results refer to the production or to the
metabolism of the substance being investigated.
Taken together, even though inflammation-related changes such as hyperemia and
edema have been detected in jejunoscopies after a lactose challenge (Banai et al
1984), and even though the symptoms of lactose intolerance resemble those seen in
inflammatory gastrointestinal diseases, our findings do not support the theory that
inflammation is related to lactose-induced symptoms. The method we used to
investigate this was not very refined, but if there had been enhanced production of
prostaglandins or NO, which are well documented as being associated with chronic
inflammation of the intestine (see Stark and Szurszewski 1992, Lefebvre 1995), this
would almost certainly have been apparent with the study design and the methods
used.
6.2.3. The hypothesis of induction of lactase by lactose
The effect of dietary modification on the expression or activity of the lactase enzyme
was tested by supplementing the diet of 8-week-old rats with lactose for seven days.
Both the expression and the activity increased compared to the control animals, who
received no lactose. The induction of lactase was most obvious in the proximal and
the middle parts of the jejunum. This accords with previous experimental studies in
which the reduced activity of lactase found in adult animals was at most doubled by
dietary modifications (Bolin et al 1969, Wen et al 1973, Goldstein et al 1974, Goda
et al 1984, Thoreux et al 1998).
In human studies, on the other hand, the continuous intake of lactose did not modify
the activity found in post-test biopsies (Cuatrecasas et al 1965, Newcomer and
McGill 1967, Kreusch et al 1969, Gilat et al 1972). But these biopsies were only
taken from the proximal small intestine before and after the study. As shown recently,
the activity of lactase varies greatly on the villus enterocytes depending on the biopsy
site (Maiuri et al 1992, Rossi et al 1997). Thus, one biopsy sample is not sufficient to
describe the overall ability of the subject, improved or otherwise, to digest lactose.
To reduce the variability of the activity due to the sampling site, and to observe the
variability between the different parts of the intestine, several samples were taken
longitudinally the length of the small intestine. To describe better the total capacity
to digest lactose we produced an indicator simply by adding the activities of single
biopsies. When this indicator was compared proportionately to the control group we
proved that lactase activity increased overall by about 35% in those animals who
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received the largest dose of lactose. This method could be further improved if the
effects of age, the total length of the small intestine and the sampling site were noted
in this indicator, for example by using suitable coefficients. In this study the effect of
these factors was minimised by using age-, weight- and sex-matched animals.
The dose of lactose with which we showed the induction of the enzyme varied
between 10-12 g/kg body weight/day. This accords with previous studies, as far as can
be concluded from the original articles (Bolin et al 1969, Wen et al 1973, Goldstein
et al 1974, Goda et al 1984, Thoreux et al 1998). In human studies with lactase
activity measured from a biopsy, the daily doses have been about one tenth of this
quantity (Cuatrecasas et al 1965, Newcomer and McGill 1967, Kreusch et al 1969,
Gilat et al 1972). But the smaller dose of lactose, about 0.5-1 g/kg body weight/day,
reduced the excretion of breath hydrogen and diminished gastrointestinal symptoms
in lactose maldigesters after a few weeks of a lactose-containing diet (Johnson et al
1993b, Hertzler and Savaiano 1996, Briet et al 1997). At the same time faecal β-
galactosidase activity doubled (Briet et al 1997) or even tripled (Hertzler and
Savaiano 1996) compared with the control periods. These authors (Johnson et al
1993b, Hertzler and Savaiano 1996, Briet et al 1997) suggest that, rather than the
induced activity of lactase, colonic bacterial adaptation was responsible. A similar
inference was made after a continuous intake of indigestible lactulose (Florent et al
1985, Flourie et al 1993).
The results of our study thus confirm the hypothesis that, in an experimental model,
lactase is induced by the continuous intake of large dose of lactose. This can also be
seen in the Western Blot analysis of intestinal homogenates from rats which received
milk for several weeks (unpublished data). Probably because of the far smaller doses
used, increased activity has not been demonstrated with humans. Continuous, more
normal doses of lactose, less than 1 g/kg body weight, have, however, reduced
gastrointestinal symptoms and the excretion of breath hydrogen and increased faecal
β-galactosidase activity (Johnson et al 1993b, Hertzler and Savaiano 1996, Briet et al
1997), all of which are indicators of a better tolerance to lactose.
Taking conjointly our three hypotheses of the possible tools for reducing lactose-
induced symptoms, it seems that, rather than being of inflammational origin, lactose
intolerance is, at least partly, the result of motility disorders. This has also been
suggested by Hammer et al (1996), who emphasised the importance of transit time in
the occurrence of the symptoms of lactose intolerance, rather than the importance of
the amount of malabsorbed lactose. If either gastric emptying or gastrointestinal
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transit time or both can be retarded, the reduced level of the lactase enzyme in the
intestinal epithelium of a lactose maldigester may be in better state of balance with
the normal dietary intake of lactose. This reduction of motility could be achieved by
any factors, dietary or otherwise, which may retard gastric emptying and/or reduce
intestinal motility. Continuous daily intakes of lactose may further improve tolerance
to lactose by inducing the lactase enzyme, or at least by adapting the colonic bacteria
so that they ferment undigested lactose in the colon more effectively and thus reduce
the development of gastrointestinal symptoms.
6.3. How should lactose intolerance be diagnosed?
Interestingly, the self-diagnosis of lactose intolerance gave poor results. Only one
third of the self-diagnosed subjects proved to be lactose maldigesters, and some of
them, indeed, proved to be asymptomatic. Our findings accord closely with previous
studies in which lower doses of lactose (15-25 g) were used (Rosado et al 1987,
Johnson et al 1993a, Suarez et al 1995, Carraccio et al 1998, Saltzman et al 1999). In
these earlier studies the actual number of symptomatic lactose maldigesters among
self-reported maldigesters varied between 10% and 70%. Since the incidence of true
maldigesters in our studies and studies by other authors varies greatly, probably
depending mainly on the inclusion and exclusion criteria of the study subjects, this
phenomen indicates the very real need for carefully controlled clinical lactose
tolerance tests.
We also found that about one third of previously tested lactose intolerant subjects
were actually lactose digesters, according to our Golden Standard. This large ratio of
changed status in tolerance to lactose could be explained either by a truly changed
status due to the high incidence of secondary hypolactasia, or by an incorrectly made
diagnosis, either an earlier one or the new one.
The incidence of secondary hypolactasia, as well as many probable factors resulting
in it by damage to the epithelial mucosa or by the modification of gastrointestinal
motility, is not known. As the severity of inherited hypolactasia may vary, so the
severity of secondary hypolactasia may also vary according to the power and the
length of the challenge that caused it. Lactase is sensitive to factors harmful to the
mucosa, because it is located on the brush border of the mature enterocytes on the
top of the villi, and is therefore more exposed than other brush-border enzymes to
various factors affecting the jejunal mucosa (see Villako and Maaroos 1994).
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There are several factors that can lead to an incorrect diagnosis. We tried to minimise
these by using the combination of three independent test variables, and by
controlling those factors which may affect gastrointestinal motility, or may affect the
symptoms, such as dietary intake and the prior use of medication. We also used the
standard dose of lactose (50.0 g) dissolved in the standard volume of boiling water.
In Finland the lactose tolerance test is usually performed with 50 g lactose dissolved
in 200-400 ml water after an overnight fast (Peuhkuri et al 2000a). This dose equals
the lactose of a whole litre of milk and cannot be assumed to imitate the normal
symptoms produced by dietary lactose. The dose of 50 g is suitable for detecting
lactose maldigestion, but too abnormal for detecting lactose intolerance. There are
studies that describe the use a dose of 25 g with breath hydrogen analysers for
detecting lactose maldigesters (see Hamilton 1998), but more detailed studies of an
appropriate dose are needed in order to find more effectively those subjects who
really benefit from the restriction of lactose in their diets.
An exact recommendation for the volume of water in which lactose should be
dissolved is also needed. As the volume ingested affects gastric emptying (see Cooke
1975, Malagelada 1990), it can be assumed that tolerance to lactose tested with a
volume of 400 ml differs from a test performed with a smaller volume. The optimum
volume depends on the dose of lactose used. In principle, 1 g lactose can be dissolved
in 5 ml room-temperature water or in 2.6 ml boiling water. If the lactose is dissolved
in boiling water, a proper cooling to room temperature may improve the reliability of
the test, since gastrointestinal symptoms produced by the room-temperature solutions
are minor compared with those produced by cold or hot solutions, as we have shown.
The volume used may be taken from everyday drinking patterns. ‘A glass’ (200 ml)
seems to be the natural volume that can be swallowed without distaste and without
the symptoms induced by the larger volume of liquid after an overnight fast.
We found that, compared to the Golden Standard, on its own none of the test
variables used in this study was particularly good for recognising both the lactose
maldigesters and the digesters, though on average, the sensitivity and the specificity
of the variables used were good. The urine galactose test showed the best sensitivity
and the breath hydrogen test the best specificity. The total number of misdiagnosed
subjects was at most 9% if the blood glucose test was used on its own. However, it
should be borne in mind that the predictive value of each test depends on the
prevalence of lactose maldigestion in the study group. In our study the incidence of
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lactose intolerance was much higher than in a normal cross-section of the Finnish
population.
If these two variables are taken in conjunction, the reliability of the lactose tolerance
test may improve. The best combination may be to consider the measurements both
of excreted breath hydrogen and of urinary galactose. The urinary galactose test
showed the highest sensitivity, recognising 100% of the lactose maldigesters; the
breath hydrogen test was best for specificity, detecting 94% of the lactose digesters. It
would seem possible to look at the results of these two tests together, since a three-
hour urine collection is recommended for excreted galactose measurement (Arola
1988b; Grant et al 1989, Buttery and Ratnaike 1995, Alvarez-Coca et al 1996) and it
is recommended that breath hydrogen measurement should be continued until the
baseline value is exceeded by at least 20 ppm or for up to three hours (see Hamilton
1998). The combined 13CO2/H2 breath test is in its present form far too cumbersome.
If, however, this could developed further, improving both sensitivity and specificity,
simplifying the equipment needed, and reducing costs, this could offer a suitable
method in the future.
When diagnosing lactose intolerance (symptomatic lactose maldigestion), the
recording of gastrointestinal symptoms should not be disparaged. Both the severity
and the intensity of symptoms increase for several hours from the ingestion of the
lactose solution, the maximum symptom scores predicted being achieved some hours
after the beginning of the test. The most common symptoms, both those that were
expected and those actually experienced, seem to be flatulence, borborygmi and
abdominal bloating. The recording of symptoms during a lactose tolerance test
should be based on the true incidence of single symptoms and should last several
hours, preferably of minimum of three.
As was seen in our study, both those who are and those who suppose themselves to be
lactose maldigesters expect to experience severe symptoms if they drink a glass of
milk. A lactose tolerance test as such may thus, in some subjects, increase the severity
and the number of gastrointestinal symptoms. One possible mechanism for this may
be via increased intestinal motor activity induced by the stress factor, which in this
case is the test situation itself. The modifying effect of emotional factors on intestinal
motility may also explain the variability of the symptoms of lactose intolerance, as has
also been shown with gastrointestinal symptoms in IBS patients (see Stam et al 1997).
This may be avoided or reduced by using a blinded test, as we did whenever possible.
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This blinding could be achieved by using lactose-free milk or another indigestible
disaccharide such as lactulose.
To conclude, in the diagnosing of lactose intolerance, based on our results and those
of other investigators, any of the laboratory test variables used for detecting lactose
intolerance is superior to self-diagnosing. A breath hydrogen measurement together
with a urine galactose test after ingestion of a room-temperature test solution in a
natural volume of water is to be recommended. The possibility of reducing the dose
of lactose from the prevalent 50 g to a more normal dietary level should be studied
further. The recording of gastrointestinal symptoms is an essential part of the
tolerance test, even if on its own it has little value in diagnosing lactose intolerance.
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7. Conclusions
• The Micro H2 breath hydrogen analyser is reliable and useful for detecting lactose
maldigestion.
• Retarding gastric emptying improves tolerance to lactose.
• With the doses used in this study, ingestion of lactose does not affect the
production of prostaglandins or nitric oxide, and thus these indicators of
inflammation seem not to be connected with the gastrointestinal symptoms of
lactose intolerance.
• Continuous ingestion of a large dose of lactose increases the expression and
activity of intestinal lactase, at least in rats.
• A need was observed to re-estimate the practical details, such as the temperature of
the test solution, in testing tolerance to lactose. The self-diagnosing of lactose
intolerance gives unreliable results.
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